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Summary 
 
Bone morphogenetic protein (BMP)-9 belongs to the transforming growth factor (TGF)-β 
superfamily and has been suggested to play a role in bone formation, hematopoiesis, glucose 
homeostasis, iron homeostasis, angiogenesis and cancer development. Using the acute carbon 
tetrachloride (CCl4) mouse model for liver injury we found that BMP-9 expression increased 
rapidly, reaching a maximum at day 3 after injection of CCl4. At this time-point, positive 
BMP-9 staining was mainly localized to the pericentral area, where hepatocytes were 
seriously damaged. Phosphorylation of Smad1, one of the main BMP’s transducing signaling 
molecules, was increased mainly in hepatocytes already at 3 h after CCl4 application, although 
some positive staining for pSmad1 was also observed in sinusoidal cells. At day 3, positivity 
was additionally detected in infiltrating cells, representing most likely proliferating, activated 
hepatic stellate cells (HSCs). Immunostainings for α-smooth muscle actin (SMA), desmin and 
cleaved caspase3 showed that at day 3, in pericentral areas the extent of hepatocyte apoptosis 
reached its peak and HSCs significantly proliferated and activated. Even though in vitro 
BMP-9 did not cause apoptosis directly, it enhanced TGF-β1-induced hepatocyte apoptosis. 
In vitro experiments demonstrated that BMP-9/Smad1 signaling was involved in the 
transdifferentiation of HSCs. In human hepatocellular carcinoma (HCC) samples, mildly 
positive (1+) BMP-9 immunostaining was observed in 25/41 (61%), and moderately to 
strongly positive staining (2+) was observed in 16/41 (39%) patients. In 27/41 (65.85%) 
patients, BMP-9 protein expression levels were consistent with the mRNA expression level as 
measured by in situ hybridization. In those patients with 2+ protein levels, nuclear pSmad1 
expression in cancer cells was also significantly increased. BMP-9 expression was positively 
correlated to nuclear Snail expression and reversely correlated to cell surface E-cadherin 
expression, although this trend did not reach statistical significance. Expression levels of 
BMP-9 were significantly correlated with the T stages of the tumors, which is a measure for 
the degree of tumor invasion. In vitro in HCC cells, similar to the findings with human 
samples, BMP-9 treatment caused a reduction of E-cadherin and an induction of Vimentin 
and Snail expression, which are characteristics of epithelial-mesenchymal transition (EMT). 
Furthermore, BMP-9 enhanced cell migration.  
 
In conclusion, these results imply that BMP-9 is involved in HSC activation and hepatocyte 
apoptosis during liver damage and regeneration, and that it acts as a tumor promoter via 
inducing EMT in HCC.   
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Zusammenfassung 
 
Bone Morphogenetic Protein (BMP)-9 gehört zur Familie der Transforming Growth Factor 
(TGF)-β Zytokine welche als Modulatoren zentraler, zellulärer Prozesse, wie Osteogenese, 
Hämatopoese, Glukosehomeostase, Eisenhaushalt, Angiogenese sowie Tumorgenese 
beschrieben wurden. In der vorliegenden Arbeit wurden die Expressionslevel von BMP-9 in 
Mäuselebern nach akuter Schädigung der Leber durch einmalige CCl4 Injektion untersucht. 
Es zeigte sich insbesondere in perivenösen Arealen der Leber eine schnelle Induktion der 
BMP-9 Expression, welche an Tag 3 ihr Maximum erreichte. Bereits 3 h nach CCl4 
Applikation konnte mittels Western blot und Immunfärbungen gegen phosphoryliertes Smad1 
eine starke Aktivierung des BMP-9 Signalweges gezeigt werden, die bis mindestens Tag 3 
erhöht blieb. Außer in Hepatozyten fand sich diese Smad1 Aktivierung auch in sinusoidalen 
Zelltypen. An Tag 3 waren auch Zellen positiv gefärbt, bei welchen es sich vermutlich um 
aktivierte hepatische Sternzellen (HSC) handelt. Immunfärbungen gegen α-smooth muscle 
actin (SMA), Desmin und aktivierte Caspase-3 deuten stark darauf hin, dass an Tag 3 nach 
CCl4 Injektion HSC im perivenösen Bereich aktiviert sind und proliferieren sowie dass 
Hepatozyten (HC) dann vermehrt in Apoptose gehen. In Zellkulturexperimenten konnte 
gezeigt werden, dass BMP-9 bei der Aktivierung primärer Maus-HSC eine Rolle spielt und 
dass es die TGF-β vermittelte Apoptose in primären Maus-HC verstärkt. In Gewebeschnitten 
von Patienten mit hepatozellulärem Karzinom (HCC) fand sich in 25/41 (61%) Patienten eine 
leicht positive Immunfärbung für BMP-9 ("1+"), und in 16/41 (39%) eine stark positive 
Färbung ("2+"). In 27/41 (65.85%) konnte darüber hinaus mittels in situ Hybridisierung eine 
Korrelation zwischen BMP-9 Protein- und mRNA-Ebene nachgewiesen werden. Des 
Weiteren korrelierte eine positive phospho-Smad1 Färbung mit erhöhter BMP-9 Expression 
("2+" Proteinebene). Tendenziell ging die BMP-9 Expression mit erhöhter Expression von 
Snail und verminderter Expression von E-Cadherin einher, diese Korrelation erreichte jedoch 
keine Signifikanz. Schließlich konnte eine signifikante Korrelation der BMP-9 Expression mit 
der Invasivität der Tumoren nachgewiesen werden. BMP-9 Stimulation von HCC Zellen in 
vitro induzierte die Expressionen von Vimentin und Snail und reduzierte die von E-Cadherin, 
ein Expressionsmuster, das charakteristisch für eine epitheliale-mesenchymale Transition 
(EMT) ist. In Korrelation zu diesen Befunden verstärkte BMP-9 auch die in vitro Migration 
von HCC Zellen.  
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Insgesamt konnte gezeigt werden, dass BMP-9 nach Leberschädigung eine wichtige Rolle bei 
der Aktivierung von HSC und der TGF-β vermittelten Apoptose von Hepatozyten spielt und 
daß es über Induktion von EMT pro-tumorigene Effekte beim HCC ausübt. 
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1. Introduction 
 
   1.1. The liver 
 
The liver is a fundamental organ for humans and most animals. It is the largest visceral organ 
and gland in the body. It has been identified to play a role in more than 500 separate functions. 
The major functions include synthesis of various amino acids, converting ammonia into urea, 
synthesis and degradation of proteins, taking part in carbohydrate metabolism, lipid 
metabolism, production of albumin, production of coagulation factors (I, II, V, VII, IX, X, XI, 
protein C, protein S and anti-thrombin), excretion of bile, detoxification and drug metabolism, 
breakdown of insulin and other hormones, storage of necessary nutrients for body health such 
as glucose, Vitamin A, Vitamin D, iron and others, and production of immune factors. 
    
   1.2. Hepatocytes and hepatic stellate cells 
  
Hepatocytes are the dominant parenchymal cell type of the liver. They account for almost 
90% of the liver mass and provide about 60% of the total number of liver cells 
(Michalopoulos and DeFrances, 1997). They execute the major functions of the liver, which 
have been mentioned above. Even though hepatocytes do not proliferate in culture, they have 
very strong proliferative potential in vivo. Owing to this potential, liver function and size can 
be restored in several days after partial hepatectomy. Hepatocytes are arranged into liver 
plates, which are separated by sinusoids. The plates are only as thick as one cell in mammals 
and sinusoids are lined with fenestrated and discontinuous endothelial cells. Between the 
hepatocyte plate and the endothelial cell lining there is the space of Disse, where lymph is 
drained into the portal tract lymphatics. When live injuries like drugs, chemical toxins (e.g., 
carbon tetrachloride), liver resection or acute viral infections occur, normally non-dividing 
mature hepatocytes start to re-enter the cell cycle and undergo mitosis to regenerate the liver. 
However, if the injury is more severe, or chronic or the mature hepatocytes have no more 
capacity because of cell senescence or arrest for liver regeneration, another type of quiescent 
cell, progenitor cells which are thought to reside in the canals of Hering will be activated. 
These cells can differentiate into either hepatocytes or cholangiocytes. Therefore liver 
regeneration can still be achieved (Riehle et al., 2011).  
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In normal liver, hepatic stellate cells (HSCs) situated in the space of Disse account for 5 - 8% 
of the whole liver cell number. In a quiescent state, HSCs are the principle cell type for 
storage of retinoids, but it is difficult to visualize them by light microscopy (Geerts, 2001). 
The function of quiescent HSCs is largely unknown so far except several studies showing that 
HSCs act as antigen-presenting cells and stimulate NKT cell proliferation (Winau et al., 2007). 
When the liver is injured, quiescent HSCs are firstly activated, followed by evolving into 
myofibroblast-like cells, which is a key step to develop liver fibrosis (Friedman, 2004). In the 
normal liver, there is low density of “basement membrane-like” extracellular matrix (ECM) in 
the Disse space as cellular support. Activated HSCs (aHSC) represent a smooth muscle 
myofibroflast-like cell type and α-SMA is a typical histological marker for these cells. The 
aHSC secretes large amounts of type I and III collagens, other extracellular matrix (ECM) and 
tissue inhibitor of metalloproteinase (TIMP)-1 that inhibits matrix-metalloproteinase-induced 
matrix degradation (Benyon and Arthur, 2001). ECM deposits in the sinusoids and 
deteriorates the liver function (Friedman, 2003). When liver injury is slight and normal 
structure and functions are preserved, deposited ECM will be dissolved within a certain 
period of time and aHSCs will most likely go to apoptosis. However, when the injury is too 
severe, HSC activation and proliferation exist constantly, which finally leads to liver fibrosis 
or even liver cirrhosis (Lafdil et al., 2006). 
 
 
                                                                                                                      (modified from (Friedman, 2003)) 
 
Fig.1. Sub-endothelial changes in response to liver injury. A, Normal liver: HSCs are quiescent and store 
Vitamin A droplets and there is low density of matrix in the space of Disse. Fenestrated endothelial lining 
supports the normal liver architecture. B, Injured liver: HSCs are activated and increase their proliferation, ECM 
accumulates, endothelial fenestrae close. Hepatocyte polarity and functions get lost.  
 
   1.3. TGF-β 
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The TGF-β family includes TGF-β isoforms, BMPs, growth and differentiation factors, 
inhibins, Muellerian inhibiting substance and activins (Piek et al., 1999). TGF-β is a 25 kDa 
cytokine which is secreted by nearly all cell types in the body in physiological as well as 
pathological conditions (Massague, 1990). There are 3 isoforms, TGF-β1, TGF-β2 and TGF-
β3 in mammals. Among them, TGF-β1 is most widely distributed and most intensively 
studied. TGF-β mediates multiple cellular responses including cell proliferation, 
differentiation, apoptosis, migration, invasion, ECM deposition and angiogenesis (Rahimi and 
Leof, 2007). As far as liver is concerned, TGF-β1 has been reported to play crucial roles in 
liver repair since it has inhibitory effects on proliferation of hepatocytes and exerts fibrogenic 
functions on HSCs (Bedossa and Paradis, 1995).      
     
   1.4. BMP-9 
 
Bone morphogenetic proteins (BMPs) are a subgroup belonging to the TGF-β superfamily. 
Until now, more than 15 kinds of BMP-related proteins have been discovered (Miyazono et 
al., 2005). They were divided into 4 subgroups according to the similarity of their amino acid 
sequences and functions. The BMP-2/4 subgroup includes BMP-2, BMP-4 and the 
Drosophila dpp, functioning in embryonic development. The BMP-7 subgroup is composed 
of BMP-5, 6, 7, 8 and the Drosophila gbb. The third is the GDF-5 subgroup, including GDF-5, 
6 and 7. These three subgroups are important for keeping up normal tissue functions. BMP-9 
and BMP-10 are the two members of a fourth subgroup, whose functions are now being 
discovered (David et al., 2009). Current studies have implicated that some BMPs function in 
cancer progression and may be potential therapeutic targets for cancer treatment (Li, 2008). 
    
BMP-9, also termed growth differentiation factor-2 (GDF-2), was firstly cloned from a fetal 
mouse liver cDNA library (Celeste, 1994). The precursor human BMP-9 is constituted of 429 
amino acids with a rough molecular weight of 47 kDa. Following post-transcriptional 
modification, the immature precursor is divided into a pro-region and a mature region (13 
kDa). However, both dimers of mature regions and BMP-9 pro-region complexes have the 
same biological functions after secretion (Brown et al., 2005). In physiological conditions 
BMP-9 circulates in serum and plasma at a concentration of about 5 ng/ml (Herrera and 
Inman, 2009). Emerging evidences indicate that BMP-9 participates in various physiologic 
processes such as bone formation, hematopoiesis, glucose homeostasis, iron homeostasis and 
angiogenesis (Bessa et al., 2009; Chen et al., 2003; Suzuki et al., 2010; Truksa et al., 2006). 
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Like other BMPs, BMP-9 has also been suggested to be involved in cancer development in a 
small number of studies. But its effects on different cancer cells are controversial. This might 
be due to tissue differences and cellular environments where BMP-9 is expressed. Blanca 
Herrera et al reported that about 25% of epithelial ovarian cancers express BMP-9, but normal 
human ovarian surface epithelial specimen do not. Furthermore, some ovarian cancer cell 
lines can acquire autocrine BMP-9 signaling to facilitate cancer cell proliferation (Herrera et 
al., 2009). On the contrary, in prostate cancer, BMP-9 suppresses cancer cell growth via 
inducing cell apoptosis (Ye et al., 2008). In breast cancer cells it inhibits growth, migration 
and invasion (Wang et al., 2011). Song et al reported that BMP-9 induces cell proliferation in 
a HCC cell line, HepG2 and sub-confluent rat primary hepatocytes (Song et al., 1995), 
however, possible roles for BMP-9 in liver diseases have been largely unknown so far.  
 
   1.5. Signal transduction pathways initiated by TGF-β or BMPs 
 
TGF-β superfamily members signal via two canonical pathways, the Smad pathways and via 
non-canonical pathways, the non-Smad pathways. By now, also receptor tyrosine kinases, 
cytokine receptors and G-protein-coupled receptors have been described to mediate TGF-β 
signaling (Derynck and Zhang, 2003).  
 
      1.5.1. Smad signaling 
 
Signal transduction induced by TGF-β isoforms is initiated by the binding of a ligand to its 
corresponding type II receptor, which triggers association and complex formation with a type 
I receptor which gets transphosphorylated by the type II receptor. There are 5 type II receptors 
and 7 type I receptors which have special affinities to certain ligands. Both types of receptors 
possess serine/threonine kinase activity and can phosphorylate and thereby activate the down-
stream molecules termed Smads (ten Dijke and Hill, 2004).  
 
 16 
 
                                                                                                  (modified from (Shi and Massague, 2003)) 
 
Fig.2. TGF-β superfamily ligands signal through specific type I and II receptors and activate Smad1/5/8 or 
Smad2/3 pathways, resulting in the regulation of expression of target genes. In vertebrates some accessory 
receptors further modify the signaling of TGF-β superfamily members. 
GDF-growth and differentiation factor (Vg1 in Xenopus), MIS- Mülerian inhibiting substance (also known as 
AMH- anti-Mülerian hormone). 
 
Smads are intracellular transcription factors in mammalian cells, and in Drosophila and C. 
elegans they are named as MAD and Sma, respectively (Derynck, 1998). Until now 8 Smad 
family members have been identified and according to their function they have been divided 
into three subfamilies: Smad1, Smad2, Smad3, Smad5 and Smad8 are defined as receptor-
activated Smads (R-Smads) which become phosphorylated by a type I receptor, the common 
mediator Smad (Co-Smad) Smad4 which forms complexes with the activated R-Smads and 
inhibitory Smads (I-Smads: Smad6 and Smad7), which antagonize the signaling of TGF-β 
family members (Park, 2005). There are two conserved domains: the N-terminal Mad 
Homology 1 (MH1) domain and the C-terminal MH2 domain in both R-Smads and Smad4 
(ten Dijke and Hill, 2004). But I-Smads do not share the conserved MH1 domain with R-
Smads and Smad4, which is the reason that I-Smads can not bind DNA. The MH2 domain is 
highly conserved in all three types of Smads and is responsible for receptor interactions (Shi 
and Massague, 2003). The type I receptor phosphorylates the R-Smads on a C-terminal SSXS 
(Ser-Ser-X-Ser sequence) motif (ten Dijke and Hill, 2004).  
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                                                                                                  (From (Miyazono et al., 2010)) 
 
Fig.3. Schematic structure of R-Smads, co-Smad and I-Smads. In the linker region green squares represent the 
phosphorylation site of R-Smads and I-Smads, and yellow circles represent the PXS/TP (or S/TP) motif which is 
potentially phosphorylated by MAP kinases. MH1 domains are shown in red and MH2 domains in blue. 
SSXS: C-terminal phosphorylation site of R-Smads. 
 
There have been two Smad signaling cascades identified: the classical TGF-β branch 
including phosphorylation of Smads 2 and 3 which is activated by TGF-β, nodal, activin and 
myostatin, and the BMP branch involving phosphorylation of Smads 1, 5 and 8 which is 
initiated by BMPs and GDFs (Moustakas and Heldin, 2003). TβR-II and ALK5 are the main 
receptors involved in the TGF-β branch. TGF-β and activin possess higher affinity to TβR-II 
and can not bind to the type I receptor alone. In contrast to this, some BMPs including BMP-9 
display higher affinity for their type I receptors, than for their type II receptors. The BMP-
type I receptor group contains BMP receptor type IA (BMPR-IA/ALK3), type IB (BMPR-
IB/ALK6), activin receptor-like kinase-1 (ALK-1) and ALK2. The typeII receptors are 
composed of BMP receptor type II (BMPR-II), activin A receptor type IIA (ActRII) and 
activin A receptor type IIB (ActRIIB). After its binding to BMPs, the type II receptors 
phosphorylate the type I receptors, BMPs are known to activate only the Smad 1/5/8 pathway 
but do not lead to activation of Smads 2/3. The combination of R-Smads with Smad4 
facilitates the translocation of the complex into the nucleus, which then mediates the 
transcription of BMP-target genes. This pathway is regarded as the canonical BMP/Smad 
pathway (Miyazono et al., 2010). Which Smad-pathway is being activated under a given 
situation is determined by the type I receptor being bound by the ligand (Lopez-Coviella et al., 
2006).  
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Activin receptor-like kinase-1 (ALK1) is a type I receptor with serine/threonine kinase 
activity on the cell surface, which participates in the Smad1/5/8 singnaling pathway (David et 
al., 2007). Several studies have demonstrated that ALK1 is mainly expressed in vascular 
endothelial cells and is involved in blood vessel formation during embryogenesis and wound 
healing (Roelen et al., 1997) as well as tumor angiogenesis (Lamouille et al., 2002). A 
mutation in the ALK1 gene causes hereditary hemorrhagic telangiectasia (HHT), a disease 
characterized by autosomal dominant vascular dysplasia (Johnson et al., 1996). Genetic 
deletion of ALK1 in mice results in embryonic lethality attributed to defects in angiogenesis 
(Urness et al., 2000). Endothelial-targeted ALK1 gene disruption leads to dilated vessels in 
the yolk sac without capillary beds which normally connect arteries and veins, which is 
similar to the characteristics of HHT (Park et al., 2008). Besides TGF-β1 and TGF-β3 which 
may activate ALK1 in some cell types (Lux et al., 1999), BMP-9 and BMP-10 have been 
identified as highly specific ligands for ALK1 (David et al., 2007).  
     
Smad1 was the first cloned mammalian Smad gene (Itoh et al., 2000). Smad1-knockout mice 
experience normal gastrolation, but die in midgestation because of defective allantois 
development and chorioallantoic placenta formation (Huang et al., 2000). Smad1-deletion can 
also result in defects of yolk sac angiogenesis (Chang et al., 2002). Smad1 transgenic mice 
show early postnatal death and impaired cell cycle of the embryonic fibroblasts (Queva et al., 
1999).  
 
      1.5.2. non-Smad pathway 
 
A large amount of in vitro cell experiments implicate that the small GTPase Ras and mitogen-
activated protein kinases (MAPKs) including ERKs, p38 and c-Jun N-terminal kinases 
(JNKs), phosphatidylinositol-3’-kinase and Src kinase are involved in non-Smad pathways of 
TGF-β family members (Moustakas and Heldin, 2005). There are three general mechanisms 
for non-Smad signaling to mediate the responses to TGF-β family members: (1) Non-Smad 
signaling directly interacts with the Smads, like phosphorylation, and modulates their activity. 
(2) The receptor complex directly modifies non-Smad proteins which induces signaling in 
parallel with the Smad pathways. (3) Smads directly influence the activity of non-Smad 
proteins. Ras and MEK have been revealed to be partially required for Smad1 
phosphorylation initiated by TGF-β1 as well as BMPs (Yue and Mulder, 2000). The 
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epidermal growth factor and hepatocyte growth factor phosphorylate Smad1 via ERK 
signaling, which inhibits BMP-induced nuclear accumulation and transcription of Smad1 
(Kretzschmar et al., 1997a). Smad1 phophorylation by JNK, ERK or p38 MAPK is necessary 
for the phosphorylation of GSK3β. GSK3β in turn phosphorylates the linker region of Smad1, 
which enhances the recruitment of Smurf1, an ubiquitin ligase, facilitating suppression of the 
transcriptional activity of Smad1, resulting in proteasomal degradation of activated Smad1. 
Fibroblast growth factor can activate MAPKs, thereby reducing BMP/Smad1 signaling. Wnt 
inhibits GSK3β which promotes BMP/Smad signaling (Fuentealba et al., 2007). Through 
these mechanisms, non-Smad signalings participate in cell apoptosis, EMT and migration, cell 
proliferation and matrix regulation in parallel to Smad signalings triggered by TGF-β family 
members (Moustakas and Heldin, 2005). 
 
   1.6. Liver injury by carbon tetrachloride (CCl4) intoxication 
 
Liver injury in rodents induced by CCl4 intraperitoneally represents a most widely accepted 
canonical animal model to investigate the response of acute and chronic liver injury since the 
elementary lesions caused by this hepatotoxin replicate those seen in most cases of human 
liver diseases (Taniguchi et al., 2004). In mature hepatocytes, cytochrome P-450 IIE1 
(Cyp2E1) bioactivates CCl4 to ·CCl3 free radical, which is then converted to a peroxy radical, 
CCl3O·2 (Slater, 1987). Reaction of these free radicals with polyunsaturated fatty acids 
triggers a reaction cascade which results in peroxidation of cellular lipids, proteins and DNA 
as well as injury by reactive oxygen species (ROS) (Johansson and Ingelman-Sundberg, 1985). 
Secondary liver injury comes from inflammatory reactions mediated by Kupffer cells which 
are largely activated and release important cytokines such as tumor necrosis factor (TNF)-α 
(Schumann and Tiegs, 1999). Those cytokines recruit and activate neutrophils, the latter 
releases ROS and further enhances liver injury (Louis et al., 1998). Liver damage is 
accompanied by liver repair, during which hepatocytes surrounding the necrotic area 
proliferate and the synthesis of ECM accelerates transiently.  
 
      1.6.1. Acute liver injury 
 
Normally, the CCl4-induced acute liver injury model is generated with a single injection of 1 
ml/kg, which functions as a strong regenerative stimulus. This acute model is characterized by 
inflammatory responses caused by CCl4 aiming at clearance of the tissue from the damaged 
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tissue debris, followed by the regenerative processes leading to a final restoration of the 
original liver structure and function. This acute model involves generation of oxidative stress 
and recruitment of inflammatory cells, which is reported to induce liver architectural and 
functional damage. Upon acute CCl4 hepatotoxicity, the opposing biological responses, tissue 
injury and repair are simultaneously happening (Rao et al., 1997). CCl4 causes pericentral 
liver damage (Lindroos et al., 1991) and it has been reported that centrilobular necrosis occurs 
one day after CCl4 administration in rats and mice (Louis et al., 1998; Sigala et al., 2006). 
Except hepatocyte necrosis, another type of cell death, apoptosis also occurs in the ballooned 
and damaged hepatocytes within the centrilobular area. Jialan Shi et al have found that large 
numbers of hepatocytes undergo apoptosis. The amount of apoptotic hepatocytes is increased 
at 3 h and peaks at 6 h after CCl4 intoxication in rat. Furthermore, the percentage of apoptotic 
ballooned cells is increased until day 3 (Shi et al., 1998).  
 
Genes representing liver functions like catalase, albumin, aldolase B are significantly reduced 
at 24 h and return to normal at 48 h after CCl4 injection (Taniguchi et al., 2004). Furthermore, 
liver regeneration is obviously increased, which is reflected by the mitotic activity of 
hepatocytes, with a peak between 48 and 72 hours after CCl4 intoxication (Theocharis et al., 
2000). Preceding the recovery of liver function, expression of pivotal factors such as HGF, 
NF-κB and AP-1 responsible for liver regeneration are significantly increased (Taniguchi et 
al., 2004). TGF-β1 has been regarded as a crucial player in liver repair (Bedossa and Paradis, 
1995). During liver regeneration after CCl4 induced liver injury, TGF-β1 mRNA is increased, 
reaching a peak on day 3. TGF-β1 is secreted by both hepatocytes and non-parenchymal cells 
like HSCs (Tsuchiya et al., 2007). It reduces the transcription of genes responsible for DNA 
synthesis and inhibits growth of hepatocytes (Bissell et al., 1995). Furthermore, it causes 
hepatocyte apoptosis via an oxidative stress process during which reactive oxygen species are 
produced, resulting in loss of mitochondrial-transmembrane potential, the release of 
cytochrome c and activation of caspases (Carmona-Cuenca et al., 2008). 
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                                                                                             (modified from (van Zijl et al., 2009)) 
 
Fig.4.   TGF-β induces cell cycle arrest and apoptosis in hepatocytes. 
 
At sites of damaged liver, aHSCs produce a transient scar to prevent the liver tissue from 
further damage. At the same time, aHSCs have pro-inflammatory and hepatomitogenic 
functions via secreting cytokines such as HGF and IL-6 so that the infection and cellular 
debris can be cleaned together with hepatocyte regeneration. During acute injury such aHSC 
induced wound-healing responses are rapidly resolved again due to the apoptosis of aHSCs 
(Elsharkawy et al., 2005). Whether some percentage of aHSCs might also disappear by some 
kind of “deactivation” resulting in regain of their quiescent phenotype is still under 
investigation.  
 
      1.6.2. Chronic liver injury by CCl4  
 
With chronic CCl4 exposure, the regenerative capacity of mature hepatocytes is exhausted and 
liver progenitor cells will participate in liver regeneration. Since the liver is consecutively 
injured by CCl4, the wound-healing initiated by aHSCs will not be reversed, but progresses 
until liver fibrosis and even liver cirrhosis will happen (Mann and Mann, 2009). Ample 
evidences point to a critical role of TGF-β in the activation and transdifferentiation of HSCs, 
leading to CCl4-induced liver fibrogenesis (De Bleser et al., 1997; Doh et al., 2008; Jeong et 
al., 2006). Treatment strategies aiming at neutralization of TGF-β or inhibition of its pathway 
have been proven to reduce and/or prevent experimental fibrogenesis (Mizuno and Nakamura, 
2007; Weng et al., 2007). However, with chronic damage the liver architecture can not be 
reversed back into the normal status any more (Weber et al., 2003), although with cessation of 
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the damaging stimulus reversion of fibrosis is until a certain point still possible whereas 
cirrhosis is considered as irreversible. 
 
 
                                                                      (modified from (Dooley et al., 2008) and (Hamzavi et al., 2008)) 
 
Fig.5. TGF-β plays a key role in HSC activation and transdifferentiation. Liver injury induces HSC activation. 
HSCs are the main source of TGF-β in injured liver which functions in paracrine and autocrine ways to mediate 
HSC activation and synthesis of ECM. Finally released TGF-β also affects other liver cells, like hepatocytes. 
 
   1.7. Hepatocellular carcinoma (HCC) 
 
Liver cirrhosis is considered as pre-stage for the development of liver cancer although in a 
small percentage of cases liver cancer also develops without pre-existing cirrhosis. 80 - 90% 
of primary liver cancer cases originate from hepatocellular carcinoma (HCC), which has been 
regarded as the fifth most common cancer and the third most fatal reason responsible for 
cancer-related death in the world (Yang and Roberts, 2010). The majority of HCC is related to 
cirrhosis, which is the end stage of various liver diseases (Calle et al., 2005; Lau and Lai, 
2008). Current therapeutic options including surgical resection, liver transplantation and 
chemoembolization can be only eligible for early stages of HCC. However, cancer recurrence 
will happen in around 50% of the patients (Josephs and Ross, 2010; Whittaker et al., 2010). 
Therefore the prognosis of HCC is nowadays still poor and HCC is inclined to tumor 
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invasiveness as well as intra- and extra-hepatic metastases formation. The main risk factors 
responsible for HCC include hepatitis B or hepatitis C infection, alcoholic liver cirrhosis, 
aflatoxin B and non-alcoholic steatohepatitis.  
 
It is accepted that both genetic and epigenetic factors initiate and promote the development of 
HCC. HCC originates from the malignant change of hepatocytes and/or hepatic stem cells 
(Sell, 2002). In healthy liver, mature hepatocytes are highly differentiated and perform the 
normal liver functions such as detoxification, drug metabolism and glucose metabolism. 
Mature hepatocytes and/or liver stem cells undergo proliferation, apoptosis, dysplasia and 
neoplasia as result from external stimuli and/or liver damages (Farazi and DePinho, 2006; 
Villanueva et al., 2007). Before neoplasia forms, activated signaling pathways may facilitate 
cell growth and at the same time, dysplastic cell clones may be selected and induced. Once 
genomic alterations like point mutations or abnormal methylation of critical gene promoters 
occurs, these dysplastic cell clones may convert into a malignant phenotype (Minguez et al., 
2009). In the progression of HCC, the cell proliferation is abnormal and hepatocytes become 
dedifferentiated. Until now, several molecular mechanisms have been reported as significant 
events in HCC including activation of Ras/mitogen activated protein kinase (MAPK) 
signaling, transforming growth factor (TGF)-β signaling, TGF-α/Epidermal growth factor, 
and Wnt/β-catenin signaling, unregulated expression of tumor suppressors like p53, Rb, and 
others (Breuhahn et al., 2006). TGF-β may provide tumor promoting effects towards 
hepatocytes via Smad and non-Smad signaling pathways (Dooley et al., 2009). BMP-4, 6, 7, 8, 
9, 10, 11, 13 and 15 are reported to be up-regulated in HCC cell lines and their enhanced 
expression levels suggest enhanced migratory and invasive activity of HCC cells dominantly 
via Smad signaling (Maegdefrau and Bosserhoff, 2012). BMP-2 induces angiogenesis in HCC 
xenografted nude mice (Qiu et al., 2010) and BMP-4 promotes HCC progression and may be 
a novel prognostic marker in HCC (Guo et al., 2012; Maegdefrau et al., 2009). 
 
   1.8. Epithelial-mesenchymal transition (EMT) 
 
EMT is characterized by loss of epithelial cells' differentiated traits including cell-cell contact, 
cell polarity as well as acquisition of mesenchymal appearances such as higher motility, 
invasiveness and resistance to apoptosis (Polyak and Weinberg, 2009). Properties 
characteristic for EMT consist of down-regulation of epithelial markers like E-cadherin and 
ZO-1, nuclear translocation of β-catenin and up-regulation of mesenchymal markers like 
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Vimentin and N-cadherin (Thiery, 2002; Yang and Weinberg, 2008). The zinc-finger 
transcription factors Snail and Slug, the basic helix-loop-helix transcription factors Twist,  
E47 and E2-2, the ZEB family factors ZEB1 and ZEB2, and the inhibitors of 
differentiation/DNA-binding (Ids) have been described to drive EMT (Bolos et al., 2003; 
Peinado et al., 2007; Yang et al., 2004). The EMT program has been demonstrated to play a 
central role in pathophysiological conditions including normal embryogenesis and wound 
healing, but also carcinogenesis. EMT first occurs during gastrulation of the embryonic 
development, in which the epithelial cells are converted into mesenchymal cells and the three-
layered embryo forms (Thiery and Sleeman, 2006). Furthermore, EMT takes significant parts 
in the process of organogenesis when the heart, craniofacial structures, the cardiac valves and 
the secondary palate form (Polyak and Weinberg, 2009). EMT is further implicated in wound 
healing. In the epidermis, the adhesiveness of the epithelial cells is reduced as a consequence 
of injury with increasing migratory potential to remold the intact epithelial layer (Bissell and 
Radisky, 2001). This is an example for regenerative repair ascribed to EMT. EMT has also 
been mentioned in fibroproliferative wound healing, for instance, in the liver, which is 
specially dominated as liver fibrosis. One previous study in our group has addressed EMT of 
hepatocytes and participation of such cells in liver fibrosis. Adult primary mouse hepatocytes 
can lose their epithelial characteristics with TGF-β stimulation, showing loss of E-cadherin 
and up-regulation of Snail, a key transcriptional factor repressing E-cadherin (Dooley et al., 
2008), and this process seems to participate in liver fibrogensis. In addition, hepatocytes 
isolated from cirrhotic livers acquire a fibroblastoid phenotype with expression of Vimentin 
and Collagen, whereas hepatocytes from normal healthy livers are different, having 
completely epithelial traits (Nitta et al., 2008). In carcinogenesis, EMT has been recognized as 
a paramount player contributing to cancer invasion, metastasis, intratumoural heterogeneity 
and resistance capacity to therapy, which leads to poor clinical prognosis in various 
malignancies (Sabbah et al., 2008). EMT can be initiated by various mediators such as 
signaling pathways (TGF-β signaling, Wnt signaling, Notch signaling and others), tumor-
stromal interaction, hypoxia, microRNA and epigenetic regulators (Polyak and Weinberg, 
2009).  
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                                                                                             (modified from (van Zijl et al., 2009) ) 
 
Fig.6. The involvement of EMT in physiological and pathophysiological events. 
 
As for HCC, growing evidences indicate a central role of EMT in tumorigenesis. TGF-β 
signaling has a dual role in hepatic carcinogenesis. In healthy liver and at the early stage of 
HCC, TGF-β performs cell cycle arrest and apoptosis, whereas at later stages, it causes cell 
dedifferentiation and EMT (Gotzmann et al., 2002). TGF-β1 activates diverse factors and 
signaling pathways such as cyclooxygenase-2, platelet derived growth factor (PDGF), 
PI3K/Akt pathway, which facilitate the induction of EMT (Ogunwobi et al., 2012). Histone 
deacetylase 1 might be necessary for TGF-β induced EMT in HCC (Lei et al., 2010). Except 
the universal mediators for EMT, some liver specific factors contribute to EMT too. EMT in 
HCC is coupled with reduction of HNF-4 (hepatocyte nuclear factor), a transcription factor 
specific for hepatocyte differentiation and HNF-4α1 facilitates the reversion of the epithelial 
phenotype from a progressive one in rapidly growing HCC cells (Lazarevich et al., 2004). 
HCC cell experiments indicate that HCV core proteins strengthen tumor-promoting functions 
of TGF-β signaling by inducing EMT in human HCC cells, leading to strong reduction of E-
cadherin. Furthermore, HBV-encoded protein HBX facilitates EMT through up-regulation of 
STAT5b (Battaglia et al., 2009; Lee et al., 2006). Hepatocyte growth factor (HGF) has also 
been reported to induce EMT in HCC via c-met signaling, Akt and COX-2 pathways 
(Ogunwobi and Liu, 2011; You et al., 2011).  
    
   1.9. Cell apoptosis 
 
Apoptosis is a type of programmed cell death characterized by nuclear fragmentation, 
chromatin condensation, shrinkage of the cell and membrane blebbing (Danial and Korsmeyer, 
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2004). It plays crucial roles in developmental processes, deprivation of altered cells such as 
cancer cells and tissue remodeling during wound healing which is executed by the activation 
of caspases (a cystein-dependent aspartate specific protease). Caspases are highly conserved 
proteases that perform the cleavage between a cystein and an aspartic residue on their 
substrates. Until now 14 caspases have been discovered and most of them play a role in 
apoptosis. There are 2 subgroups of caspases: initiator caspases (caspase2, 8, 9 and 10) and 
effector caspases (caspase3, 6 and 7).  Both the so called extrinsic and the intrinsic pathways 
can activate caspases. The extrinsic one is regulated by death receptors, primarily members of 
the tumor necrosis factor receptor (TNFR) family, like Fas-FasL on the cell surface, resulting 
in activation of caspase8. The intrinsic pathway is initiated by cytotoxic injury or 
developmental cues like stress, ionizing radiation, viral infection or DNA damage, and is 
strictly controlled by Bcl-2 family members, leading to the release of cytochrome c from the 
mitochondria, formation of the apoptosome composed of caspase 9 and apoptotic protease-
activator factor-1 (APAF1) (Youle and Strasser, 2008). Activation of caspases8 or 9 triggers 
the activation of caspases3, 6 and 7 causing the typical features of cell apoptosis (Thornberry 
and Lazebnik, 1998).  
     
The Bcl-2 family of proteins is crucial for the intrinsic pathway and includes 2 classes: anti-
apoptotic members like Bcl-2, Bcl-xL and Mcl-1, and pro-apoptotic members like Bax, Bcl-xS, 
Bad, Bim, Bak, Bmf, Bok, Noxa and Bid. They are composed of several structural domains: 
the hydrophobic domains in the BH1, BH2 and BH3 regions, and the amphipathic alpha-helix 
domain in the BH3 region (Burlacu, 2003; van Delft and Huang, 2006). The pro-apoptotic 
members can be divided into 2 subgroups: one containing 3 domains like Bax, Bak and Bok, 
and another with only the BH3 domain such as Bid, Bad, Bim, Mbf, Bik and Nova.      
     
The pro-apoptotic members Bax and Bak interact with Bcl-2 and Bcl-xL in the cytoplasm. It 
was reported that BH3-only proteins directly bind and inhibit Bcl-2 and other anti-apoptotic 
members, thus de-repress Bax and Bak. And it is also postulated that BH3-only members 
directly activate Bax and Bak (Galonek and Hardwick, 2006). When there is stimulation of 
cell apoptosis, Bax, normally located in the cytosol, binds to the mitochondrial membrane, 
leading to the formation of pores termed mitochondrial voltage-dependent anion channel 
which facilitate the loss of selective ion permeability and release of cytochrome c and AIFs 
(apoptosis-inducing factors) into the cytosol (Shimizu et al., 2000). BH3-only proteins are 
controlled by transcriptional and post-transcriptional mechanisms. For instance, NOXA is 
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induced by p53 upon DNA damage. Growth factor deprivation induces the class O forkhead 
box transcription factor-3A (FOXO3A), leading to the activation of Bim (Cory and Adams, 
2002).  
 
In some conditions, the intrinsic and extrinsic pathways have a crosstalk via Bid. For example, 
in hepatocytes, caspase8, activated by the extrinsic stimuli can cleave Bid, whose cleaved 
fragments translocate into the mitochondrial outer membrane, which causes the execution of 
the intrinsic apoptosis pathway (Li et al., 1998).   
                                                                                                                       
 
                                                                                                        (From (Cory and Adams, 2002)) 
 
Fig.7. Stress (intrinsic) or death-receptor (extrinsic) pathways activate apoptosis cascades. The arbitration is 
determined by the Bcl family members for the stress pathway and by death receptors for the extrinsic pathway 
which drives a cell into apoptosis. Commitment to apoptosis is achieved by the release of cytochrome-c from the 
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mitochondria and by the release of Diablo as well as recruitment of FADD to the death receptor complex. 
Execution is demonstrated by the consecutive activation of initiator caspases (caspase9 and 8) and executer 
caspases (caspase3 and 7). 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 29 
2. Aims of the study 
 
In order to explore the potential functions of BMP-9 in the liver, we investigated expression 
and target gene regulation of BMP-9 in two settings of liver damage:  
A) a single injection of CCl4 in mice (a classic model for acute liver damage);  
B) hepatocellular carcinoma (HCC; using human patient material and HCC cell lines).  
 
The addressed questions included:  
A) Is BMP-9 up-regulated under conditions of damage?  
B) What are the BMP-9 target genes in hepatocytes?  
C) Does BMP-9 play a role in hepatocyte apoptosis?  
D) Is the BMP/Smad1 pathway involved in hepatic stellate cell (HSC) activation and their 
subsequent fibrogenic transdifferentiation to myofibroblasts?  
E) Is BMP-9 potentially pro- or anti-carcinogenic in HCC?  
    
The role of BMP-9/Smad1 signaling was assessed by in vivo experiments using the acute 
CCl4-induced model of liver injury in mice and with in vitro experiments using primary 
cultures of hepatocytes or HSCs. To acquire a comprehensive view on BMP-9 effects in 
hepatocytes, a microarray analysis was performed to identify specific genes regulated by 
BMP-9 in proliferation/differentiation, apoptosis, iron homeostasis, sugar metabolism and 
others. Since epithelial-mesenchymal transition (EMT) is known to be critically involved in 
carcinogenesis, the influence of BMP-9 and its correlation with expression of EMT markers 
and invasiveness was analyzed in HCC cells and in human samples. 
     
In conclusion, the study may have significant implications for delineating the roles of BMP-9 
in the physiology and pathology of the liver and may aid to develop new therapeutic strategies 
for the treatment of liver diseases and/or liver cancer.  
 
 
 
 
 
 
 
 30 
3. Materials and Methods 
 
   3.1. Media, buffers and reagents  
 
      3.1.1. Cell culture reagents 
 
DMEM, Dulbecco’s Modified Eagle’s Medium with 25 mM Hepes and 4.5 g glucose per 500 
ml (Lonza, Basel, Switzerland). 
Williams’ medium E, with sodium bicarbonate, without L-glutamine and phenol red (Sigma-
Aldrich, Munich, Germany). 
Trypsin, 10x (2.5% in PBS w/o Calcium and Magnesium) (PAA Laboratories, Darmstadt, 
Germany). 
HBSS, Hank’s buffered salt solution without Calcium and Magnesium (PAA Laboratories, 
Darmstadt, Germany). 
Penicillin/Streptomycine, stock solution 10000 U/ml and working solution 100 U/ml 
(Biochrom KG, Berlin, Germany). 
L-Glutamine, stock solution 200 mM and working solution 4 mM (Lonza, Basel, 
Switzerland). 
FCS, fetal calf serum (Invitrogen, Karlsruhe, Germany). 
Dexamethasone, working solution 100 nM (Sigma-Aldrich, Munich, Germany). 
Trypan blue solution, stock solution 0.4% (Sigma-Aldrich, Munich, Germany).  
 
      3.1.2. Cytokines 
 
BMP-9, recombinant human Bone Morphogenetic Protein-9 (rhBMP-9; R&D Systems, 
Wiesbaden-Nordenstadt, Germany). 
TGF-β1, recombinant human Transforming Growth Factor-β1 (rhTGF-β1; R&D Systems, 
Wiesbaden-Nordenstadt, Germany). 
PDGF-BB, recombinant human Platelet-derived Growth Factor-BB (rhPDGF-BB; PeproTech 
GmbH, Hambourg, Germany). 
BMP-2, recombinant human Bone Morphogenetic Protein-2 (rhBMP-2; R&D Systems, 
Wiesbaden-Nordenstadt, Germany). 
BMP-6, recombinant human Bone Morphogenetic Protein-6 (rhBMP-6; R&D Systems, 
Wiesbaden-Nordenstadt, Germany). 
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      3.1.3. Inhibitors 
 
Dorsomorphin, BMP/Smad1 signaling inhibitor (Miltenyi Biotec, Bergisch Gladbach, 
Germany). 
 
      3.1.4. Buffers and reagents for Western blot 
 
RIPA buffer, 50 mM Tris-Cl (pH 7.5), 150 mM NaCl, 1% Nonidet P-40 (NP-40), 0.5% 
sodium deoxycholate, 0.1% SDS.  
Complete proteases inhibitor cocktail, (Roche, Mannheim, Germany).  
Phosphatases inhibitor cocktail II, (Sigma-Aldrich, Munich, Germany). 
NuPAGE MOPS SDS running buffer, (20x) (Invitrogen, Karlsruhe, Germany).  
NuPAGE transfer buffer, (20 x) , for 1 L 1x buffer dilute 50 ml 20x buffer in 750 ml 
distilled water and 200 ml methanol (Invitrogen, Karlsruhe, Germany). 
10x TBS, Tris-buffered-saline: dissolve 12.10 g Tris-base and 87.66 g NaCl (both: Merck, 
Darmstadt, Germany) in 800 ml distilled water, adjust pH to 7.6 and add water to 1000 ml. 
TBST, dilute 100 ml 10x TBS in 895 ml distilled water and add 5 ml 20% Tween20 solution 
(Bio-Rad Laboratories, Hercules, CA). 
Ponceau S solution, (Sigma-Aldrich, Munich, Germany).  
Stripping buffer, (Thermo scientific, Dreieich, Germany).  
Blocking solution, 5 g non-fat milk power dissolved in 100 ml 1x TBS. 
1M DTT, 0.154 g Dithiothreitol (Sigma-Aldrich, Munich, Germany) dissolved in 1 ml 
distilled water, store aliquots at -20°C. 
NuPage LDS sample buffer, (4x) (Invitrogen, Karlsruhe, Germany).  
Super Signal west dura luminol/enhancer solution, (Thermo scientific, Dreieich, Germany). 
PageRulerPlus Prestained Protein Ladder, (Fermentas, St. Leon-Rot, Germany). 
Protein standard, Bovine albumin, Fraction V (Sigma-Aldrich, Munich, Germany) diluted in 
RIPA buffer at concentrations of 1, 2, 4, 6 and 8 μg/μl was used as a standard to determine the 
protein concentration of samples. 
 
      3.1.5. Buffers and reagents for immunohistochemistry staining 
 
Xylene, (Sigma-Aldrich, Munich, Germany).  
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Ethanol absolute, (Sigma-Aldrich, Munich, Germany).  
Dual endogenous enzyme block, (DakoCytomation, Hamburg, Germany). 
1mM EDTA, dilute 0.372 g EDTA (Ethylenediaminetetraacetic acid, Calbiochem, Darmstadt, 
Germany) in 1 L dH2O and adjust pH to 8.0. 
PBS, Phosphate buffered saline: dilute 9.55 g Instamed 9,55 g/l, PBS Dulbecco, w/o Ca2+, 
Mg2+ (Biochrom, Berlin, Germany) in 1 L dH2O.  
DAB, 3,3'-diaminobenzidine tetrahydrochloride (Sigma-Aldrich, Munich, Germany).  
0.05 M Tris, (hydroxymethyl) aminomethane pH 7.6, 6.057 g of hydroxymethyl 
aminomethane (Serva, Dossenheim, Germany) was diluted in 1000 ml distilled water and 
adjusted to pH 7.6. 
H2O2, (Merck, Darmstadt, Germany). 
Malinol, (Waldeck GmbH, Muenster, Germany). 
Hematoxylin, Hematoxylin-Solution, modified according to Gill III, (Merck, Darmstadt, 
Germany). 
Phosphate buffered Formaldehyde 4%, (Sigma-Aldrich, Munich, Germany). 
EnVision+ System-HRP (DAB) for rabbit, (DakoCytomation, Hamburg, Germany). 
 
      3.1.6. Buffers and reagents for immunofluorescent staining of monolayer cell 
cultures 
   
Fixative solution, dissolve 20 g paraformaldehyde (Sigma-Aldrich, Munich, Germany), 50 μl 
1 M CaCl2 (Sigma-Aldrich, Munich, Germany) and 50 μl 1 M MgCl2 (Sigma-Aldrich, 
Munich, Germany) in 500 ml heated PBS (to 80°C) and adjust pH to 7.4. Final concentration: 
4%. Aliquots were stored at -80°C.  
Permeabilization solution, dilute 150 μl Triton-X-100 (Sigma-Aldrich, Munich, Germany) 
in 50 ml HBSS.   
Blocking solution, 1% (w/v) BSA in HBSS: 1 g Bovine albumin, Fraction V, (Sigma-Aldrich, 
Munich, Germany) diluted in 100 ml HBSS.  
0.1% Tween20 solution, dilute 250 μl 20% Tween20 solution (Bio-Rad Laboratories, 
Hercules, CA) in 50 ml HBSS. 
AlexaFluor 488 (green) 555 (red) 633 (far red) secondary antibodies, (Invitrogen, 
Karlsruhe, Germany). 
DRAQ5, fluorescent nuclear staining (NEB, Canada). 
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DAKO Cytomation Fluorescent Mounting Medium, (DakoCytomation, Hamburg, 
Germany). 
 
      3.1.7. Buffers and reagents for in situ hybridization  
 
SP6 or T7 RNA polymerase, 20 U/µl, (Fermentas, St. Leon-Rot, Germany). 
NucleoSpin® TriPrep purification system, (Macherey-Nagel, Düren, Germany). 
Hexamer primers, (Fermentas St. Leon-Rot, Germany). 
AMV reverse transcriptase, (Promega, Madison, USA). 
DreamTaq, 5 u/μl, (Fermentas St. Leon-Rot, Germany). 
DNA extraction kit, NucleoSpin® Extract II, (Macherey-Nagel, Düren, Germany). 
DIG 10x nucleotide mix, (Roche, Mannheim, Germany). 
Fat pen, (Vector Laboratories, Loerrach, Germnay). 
Alkaline phosphatase-coupled anti-digoxigenin antibody, at a dilution of 1:1000 in B-
Block (Roche/Boehringer, Mannheim, Germany).  
Alkaline phosphatase-coupled anti-fluorescein antibody, at a dilution of 1:1000 in B-
Block (Roche/Boehringer, Mannheim, Germany).  
0.2% Glycin,  dissolve 0.5 g Glycin (DakoCytomation, Hamburg, Germany) in 250 ml 1x 
PBS.  
Proteinase K, (Stock: 10mg/ml, DakoCytomation, Hamburg, Germany) diluted in 1x PBS. 
4% PFA, heat 150 ml water to 60°C. Add 8 g PFA (Paraformaldehyde; Sigma-Aldrich, 
Munich, Germany), 1 ml 2 N NaOH and 20 ml 10x PBS. Wait till the solution is clear, and 
adjust the pH to 7.4 with 1 N HCl (ca. 1400 µl). Fill up to 200 ml with water and let it cool 
down. 
4% PFA + 0.2% Glutaraldehyde, dilute1.6 ml Glutaraldehyde (Sigma-Aldrich, Munich, 
Germany) in 200 ml 4% PFA in 1x PBS. 
1x PBS+Tween, add 10 ml 10% Tween20 (Bio-Rad Laboratories, Hercules, CA) to 1 ml 1x 
PBS. 
B-Block, dissolve 1 g Boehringer Block (Roche/Boehringer, Mannheim, Germany) in 45 ml 
1x PBS +Tween in a water bath at 65°C. After cooling add 5 ml sheep/goat serum. Aliquots 
are stored at -20°C. 
NTM pH9.5, mix 25 ml 1 M Tris-HCl pH 9.5, 5 ml 5 M NaCl with 12.5 ml 1 M MgCl2 and 
add Milipore-water (Milipore, Schwalbach, Germany) to 250 ml. 
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20x SSC, 175.3 g of NaCl and 88.2 g of sodium citrate were dissolved in 800 ml distilled 
water. The pH was adjusted to 4.5 and the end volume was adjusted to 1000 ml followed by 
autoclaving to be sterile. 
2x SSC, dilute 50 ml 20x SSC pH 4.5 in 450 ml Milipore-water. 
50% Formamid/2x SSC, mix 50 ml 20x SSC pH 4.5 with 250 ml 100% Formamide, then 
add Milipore-water to 500 ml. 
10x PBS, dissolve 1.37 M NaCl 80.1 g, 0.027 M  KCl 2.0 g, 0.015 M KH2PO4 2.0 g, 0.065 M  
Na2HPO4 x 2H2O 11.6 g and Na2HPO4 x12H2O 23.3 g in 800 ml distilled water, adjust pH to  
7.2-7.4 and add water to 1000 ml. 
HYBmix,  mix 5 ml Formamide, 2.5 ml 20x SSC pH 4.5, 100 mg Boehringer Block and 2 ml 
Milipore-water in a water bath at 65°C, add 100 µl 0.5 M EDTA pH 8.0, 100 µl Tween20 
(10%), 100 µl 10% CHAPS, 4 µl Heparin (50 mg/ml) and 200 µl tRNA (50 mg/ml) (denature 
at 95°C for 5 min immediately before adding to the HYBmix). 
Aquatex, mounting medium (Merck, Darmstadt, Germany). 
NBT/BCIP, 20 μl/ml, (Roche/Boehringer, Mannheim, Germany). 
INT/BCIP, 7.5 μl/ml, (Roche/Boehringer, Mannheim, Germany). 
 
      3.1.8. Buffers and reagents for RT-PCR 
 
High Pure RNA isolation kit, (Roche, Mannheim, Germany). 
50x TAE buffer, dissolve 121 g Tris base in 250 ml dH2O, add 28.6 ml acetic acid and 50 ml 
0.5 M EDTA pH 8.0, finally add dH2O to 500 ml.  
1x TAE buffer, dilute 20 ml 50x TAE buffer in 980 ml dH2O. 
Agarose gel, dissolve Universal agarose 1.5 g (Axon, Urbach, Germany) in 100 ml 1x TAE 
buffer in the microwave for 2 min, add 3 µl Ethidium Bromide solution 10 mg/ml (Sigma-
Aldrich, Munich, Germany).  
Reverse transcription kit, (Roche, Mannheim, Germany). 
Trizol reagent, (GIBCO BRL, Eggenstein, Germany). 
Chloroform, (Carl Roth GmbH, Karlsruhe, Germany). 
Isopropanol, (VWR International GmbH, Darmstadt, Germany). 
 
      3.1.9. Reagents for animal experiments  
 
CCl4, carbon tetrachloride (Sigma-Aldrich, Munich, Germany).  
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Fluitest GOT AST kit, (Analyticon, Lichtenfels, Germany). 
Fluitest GPT ALT kit, (Analyticon, Lichtenfels, Germany). 
Fluitest LDH kit, (Analyticon, Lichtenfels, Germany). 
 
      3.1.10. Reagents for Caspase3 assay 
 
Cell lysis buffer, 50 ml of 100 mM HEPES, 13.3 ml of 750 mM NaCl, 0.1 g of CHAPS, 0.1 
ml of 100 mM EDTA and 0.1 ml of 1 M DTT are mixed and adjusted to 100 ml with pH7.4. 
Assay buffer, 50 ml of 100 mM HEPES, 13.3 ml of 750 mM NaCl, 0.1g of CHAPS, 0.1 ml 
of 100 mM EDTA, 1 ml 1M DTT and 10 ml Glycerol are mixed and adjusted to 100 ml with 
distilled water. 
AC-DEVD-AFC (substrate), 5 mg Caspase3 substrate AC-DEVD-AFC is dissolved in 5 ml 
DMSO and aliquots are stored in -20°C (Biomol, Hamburg, Germany). 1:20 dilution of the 
stock solution is prepared in assay buffer for the experiments. 
 
   3.2. Cells and cell culture 
  
      3.2.1. Isolation of primary hepatocytes and their culture 
 
Mouse hepatocytes were isolated from male C57/BL6 mice (8 - 13 weeks old) using 
collagenase perfusion. Hepatocyte isolation from mice was approved by the animal 
experimental committees and all animals received humane care in compliance with the 
German Animal Protection Act. They were housed in the standard animal house at the 
University-Hospital Mannheim. Mice were anesthetized with intraperitoneal injection of 
ketamine hydrochloride 10% (115.34 mg/ml; Essex Tierarznei, Munich, Germany; 5 mg/100 
mg body weight) and xylazine hydrochloride 2% (23.32 mg/ml; Bayer Leverkusen; 1 mg/100 
mg body weight). BASAL HANKS solution was prepared with 8 g NaCl, 0.4 g KCl, 3.57 g 
Hepes, 0.06 g Na2HPO4 x 2 H2O, 0.06 g KH2PO4 in 1 L distilled H2O, which was adjusted to 
pH 7.4 and sterilized. HANKS solution I was comprised of BASAL HANKS solution with 
2.5 mM EGTA, 0.1% glucose and penicillin/streptomycin diluted at 1:100. HANKS solution 
II was obtained by supplementing BASAL HANKS solution with 0.3 mg/ml collagenase 
CLSII and 5 mM CaCl2. HANKS solution I and HANKS solution II were pre-warmed in a 
water bath at 42°C. Collagenase was supplemented right before liver perfusion. The 
abdominal cavity was exposed under sterile conditions and the portal vein was punctured with 
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a 24 G catheter which was connected with a silicon tube (2.4 mm diameter). The mouse liver 
was perfused with HANKS solution I via a peristaltic pump at a perfusion rate of 8 ml/min. 
The vena cava and right hear ventricle were incised for fluent outflow. Perfusion of HANKS 
solution I lasted 2 min and HANKS solution II 5 to 7 min. After successful perfusion the 
whole liver was transferred to a sterile Petri dish and the gall bladder was removed. In the 
sterile bench, the liver capsules were removed with a pincette without damage to the live 
tissue. The perfused liver was divided into a suspension of single cells, cell clumps and debris 
with gentle shaking. The suspension was transferred to a 100 μm cell strainer and filtered. 
Then the filtrate was transferred to a 50 ml Falcon tube and washed with Williams E medium 
twice, followed by centrifugation at room temperature at 37.5 × g for 2 minutes. The cells 
were re-suspended with Williams E medium. The percentage of viable cells was determined 
by counting with trypan blue.  
    
For primary hepatocyte culture, 3 kinds of medium were prepared. Medium 1 was Williams’ 
medium E supplemented with 10% FCS, 2 mM L-glutamine, 1% penicillin/streptomycin and 
100 nM dexamethasone. Medium 2 was medium 1 without 10% FCS. Medium 3 was 
Williams’ medium E supplemented only with 2 mM L-glutamine and 1% 
penicillin/streptomycin.  
    
Isolated fresh hepatocytes were plated on collagen-coated 6-well plates at a density of 4 × 10
5
 
cells/well in Medium 1 and incubated in 5% CO2 at 37° C. After 4 hours, Medium 1 was 
replaced with Medium 2. On the second day, Medium 2 was changed to Medium 3. Cells 
were stimulated with recombinant TGF-β1 (5 ng/ml) or BMP-9 (5 - 50 ng/ml) for the 
indicated time points.  
  
      3.2.2. Isolation of primary hepatic stellate cells and their culture 
 
Hepatic stellate cells were isolated from female Balb/c mice by the pronase/collagenase 
method followed by single-step density gradient centrifugation with Nycodenz (Nyegaard Co. 
AS, Oslo, Norway) as previously described (Dooley et al., 2000). Balb/c mice (weight around 
20 g) were anesthetized and the abdominal cavity was opened under sterile conditions. The 
liver was perfused via the vena portae with HBSS buffer w/o Ca
2+
 and Mg
2+
. After enough 
perfusion, the liver was transferred to a funnel and perfused with pronase for 10 min, followed 
by being perfused with collagenase for 30 min. Then the liver was disintegrated and cell 
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suspension was obtained which was centrifuged with Nycodenz in gradient and washed 
several times. The cells were re-suspended with DMEM + 10% FCS. The percentage of 
viable cell number was determined by counting with trypan blue. The mean purity was higher 
than 95%. The cells were cultured in DMEM medium, supplemented with 4 mmol/L L-
Glutamine, 10% FCS and penicillin (100 IU/ml)/Streptomycin (100 µg/ml). The first change 
of medium was performed 24 h after seeding. The cells were maintained at 37°C, 5% CO2 in 
a humidified atmosphere. FCS was reduced to 0.5% for starvation overnight followed by 
stimulation with the indicated factors.  
 
      3.2.3. Cell lines and their culture 
 
Hepatocellular carcinoma cell lines HepG2 and HLE cells were cultured in DMEM 
supplemented with 10% FCS, L-glutamine and penicillin/streptomycin. 
     
HEK293A, human embryonic kidney cells were transformed by sheared human Ad5 DNA 
and were used for adenovirus amplification. Low-passaged cells were cultured in DMEM 
supplemented with 10% FCS, L-glutamine and penicillin/streptomycin. 
    
LX-2 is a human hepatic stellate cell line (Xu et al., 2005). Cells were cultured in DMEM 
supplemented with 2% FCS, L-glutamine and penicillin/streptomycin. 
 
   3.3 Animal experiments 
 
CCl4 injection in mice is a widely accepted model to study liver fibrosis and/or liver 
regeneration in vivo. All animal protocols completely complied with the guidelines for animal 
care. All mice were fed at libitum and received humane care in compliance with Heidelberg’s 
guidelines for the care and use of laboratory animals in research.  
     
30 male Balb/c mice weighing 20 - 25 g 8 weeks after birth were used in this study. Acute 
liver injury was induced by intraperitoneal injection with 1 ml/kg body weight of CCl4 (CCl4 
was prepared in a mixture with mineral oil with a ratio of 1:8), and mice were sacrificed at  3 
h, 6 h, day 1, day 2, day 3, and day 6 post injection. Mice without CCl4 injection sacrificed at 
0 h served as normal control. Blood was taken for serum parameters and livers were used for 
preparation of protein lysates (Western blot), immunohistochemistry and total RNA. 
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Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and lactate 
dehydrogenase (LDH) activities in serum from the treated mice were determined by assay kits. 
A portion of liver samples were fixed in 4% buffered paraformaldehyde for histological 
examination and immunostaining. The left were snap frozen in liquid nitrogen. 4 - 6 mice 
were used for every time point. 
 
 
 
Fig.8. Time schedule of acute CCl4 treatment and sample collection. Mice were introperitoneally injected with 
CCl4. Blood and liver tissue samples were taken at the indicated time points (3 h, 6 h, d 1, d 2, d 3 and d 6 after a 
single CCl4 injection and 0 h without CCl4 injection).  
 
   3.4. Adenoviruses  
 
      3.4.1. Virus amplification 
 
Human recombinant E1-deleted adenoviral vectors which carry a DNA construct of interest 
were amplified in HEK293A cells. The amplifications were performed with low-passaged 
HEK293A cells. HEK293A cells were cultured in DMEM plus 10% FCS till 80% confluence. 
Medium was changed. Cells were infected with viruses of moi 10 (infectious units) in DMEM 
with 10% FCS. After 48 to 96 hours, the complete cytopathic effect can be observed. Both 
cells and medium were harvested. The virus ‘soup’ can be obtained after freezing (-80°C) and 
thawing (room temperature) 3 times followed by centrifugation with 2,500 g for 15 min at 
4°C.  
 
      3.4.2. Constructs 
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No. Name Description Source 
1 
 
 
 
AdLacZ 
 
 
 
Adenovirus expressing bacterial -galactosidase 
under the control of a CMV promoter 
(constitutively active promoter comprising a 
cytomegalovirus enhancer) 
Biosciences Clontech, Palo 
Alto, CA 
 
 
2 
 
AddnALK1/2 
 
dominant negative mutant of ALK1 and ALK2 
under the control of CMV-promoter; HA-tag 
kindly provided by Dr. Peter 
ten Dijke, Leiden, Netherland 
3 
 
 
AdcaALK1 
 
 
mutant, constitutively active BMP-, Activin- or 
TGF-β receptor type I under the control of the 
CMV-promoter; HA-tag 
induced mutation: Q200D 
kindly provided by Dr. Carl-
Henrik Heldin, Uppsala, 
Sweden 
4 
 
 
AdcaALK2 
 
 
mutant, constitutively active BMP-, Activin- or 
TGF-β receptor type I under the control of the 
CMV-promoter; HA-tag 
induced mutation: Q207D 
kindly provided by Dr. Carl-
Henrik Heldin, Uppsala, 
Sweden 
5 AdSmad1 Smad cDNA under the control of CMV-promoter kindly provided by Dr. Carl-
Henrik Heldin, Uppsala, 
Sweden 
 
Tab.1. List of adenoviral constructs used in this study. 
 
      3.4.3. Infection of cell cultures 
 
Cells were plated in the morning in DMEM with 10% FCS. In the late afternoon, medium was 
changed and viruses of different moi (1, 5, 10, 15, 25, 50) were added. 24 h later, medium was 
changed. In the morning of the third day, serum starvation was performed. 4 h later, cells 
were stimulated with BMP-9.  
 
      3.4.4. Measurement of virus titer 
 
Determination of virus titer was achieved using the “Adeno-XTM Rapid Titer Kit” (BD 
Bioscience, Heidelberg, Germany). 0.5 ml HEK293A cells were plated in a 24-well plate with 
a density of 2.5 × 10
5
 cells/well in standard growth medium (DMEM + L-glutamine + 
Penicillin/Streptomycin + 10 % FCS). Descending dilutions of viral samples were prepared 
(10
-2
, 10
-3
, 10
-4
, 10
-5
, 10
-6
). 50 µl viral dilution was added to each well (each dilution was 
assayed in duplicate). After 48 h incubation at 37°C with 5% CO2, medium was removed and 
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cells were fixed with methanol at -20° for 10 min, then incubated with the primary antibody 
against viral hexon protein at 37°C for 1 hour. Cells were washed with PBS 3 times and 
incubated with the secondary antibody at 37°C for 1 hour. Positive staining (brown color) was 
visualized with DAB. Positive cells were counted under the microscope (×10) and infectious 
units (ifu/ml) were calculated according to the following formula: 
[(infected cells / field) × (fields / well)] / [(volume of virus [ml]) × (dilution factor)] = 
[(infected cells / field) × 247] / [0.05 ml × (dilution factor)] = [ifu / ml] 
The typical yield ranged between 0.5 - 2 × 10
9
 ifu/ml.  
 
      3.4.5. Determination of virus function 
 
HCC cells were infected with 0.5, 1.0, 1.5, 2.0 × 10
7
 ifu per 10
5
 cells followed by 24 h 
culturing. Cell lysates were tested in Western Blot (using specific antibody, e.g. anti-HA 
when the cells were infected with AddnALK1/2). For further experiments the smallest amount 
of virus still causing strong expression of the transgene was used.  
 
   3.5. Western blot 
 
        Western blotting was used for the analysis of protein expression.  
 
      3.5.1. Preparation of protein lysates from liver tissue 
 
50 - 100 mg liver tissue was mixed with 500 µl RIPA (containing complete protease inhibitor 
+ phosphatase inhibitor cocktail II), homogenized using an Ultraturax. The homogenate was 
centrifuged at 10,000 rpm for 10 min at 4°C. The supernatant was transferred to a fresh tube 
and the pellet containing tissue debris was disposed. Protein lysates were stored at -20°C.   
 
      3.5.2. Preparation of protein lysates from cultured cell  
 
Cells were washed twice with HBSS. 50 to 100 μl RIPA (depending on the cell number and 
protein content in the cells) added to the wells. Cells were scraped off with a cell scraper on 
ice, then the cell debris and RIPA buffer were transferred to fresh 1.5 ml Eppendorf tubes 
which were centrifuged with 10,000 rpm for 10 min at 4°C. The supernatant was transferred 
to a fresh tube and the pellet was disposed. Protein lysates were stored at -20°C. 
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      3.5.3. Measurement of protein concentration  
 
Protein concentrations were measured with the DC Protein Assay (Bio-Rad Laboratories, 
Munich, Germany). Each sample was prepared in duplicate into a 96-well plate and measured. 
The absorbance was read at 690 nm using a spectrophotometer (Wallac 1420 Victor, Wallac, 
Turku, Finland). Protein concentrations were calculated as an average value of double counts 
and related to the protein standard curve and blank value of RIPA. 
 
      3.5.4. Sample preparation for denaturing NuPAGE® Gel electrophoresis 
 
The volumes of protein, dH2O and the mixture of DTT and LDS sample buffer were 
calculated. The NuPage LDS sample buffer (4x) was re-warmed to 37 °C. Certain amount of 
dH2O, mixture of DTT and LDS sample buffer and protein samples were added into a 1.5 ml 
eppendorf tube. The mixture was vortexed and centrifuged shortly, followed by being heated 
to 95° C in a heating block for 5 min with shaking. After brief centrifugation the samples 
were loaded on a pre-cast NuPAGE® 4 - 12% Bis-Tris Gel. 1.5 µl of PageRulerPlus 
Prestained Protein Ladder was used as a protein marker. 
 
      3.5.5. SDS gel electrophoresis  
 
The proteins were separated on the pre-cast NuPAGE® 4 - 12% Bis-Tris Gel in the XCell 
SureLock™ Novex Mini-Cell (Invitrogen) at 145 V for 105 min. 
 
      3.5.6. Western blot 
 
XCell II blotting apparatus and XCell II Blot Module (Invitrogen) were used. The gel-
membrane sandwich was composed of chromatography paper (Whatmann 3MM, Maidstone, 
England) and nitrocellulose membrane. The proteins were transferred from a gel onto the 
nitrocellulose membrane (Pierce, Woburn, MA, USA) via blotting at 300 V and 250 mA for 2 
h (cell lysates) or 3 h (tissue lysates). 
    
Ponceau S solution was used to view whether the proteins were successfully transferred to the 
membrane. 
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      3.5.7. Antibodies for Western blot 
 
First antibodies 
Cat. No Clonality Supplied by Antibody, epitope, location Species* Dilution 
610181 Mouse- mono BD Biosciences E-cadherin h, m, r 1:1000 
sc-25778 Rabbit- poly Santa cruz 
biotechnology 
GAPDH h,m,r 1:1000 
No.A2547 Mouse-mono Sigma α-SMA, N-terminal peptide h, m, r 1:1000 
A-5441 Mouse-mono Sigma β-actin, N-terminal peptide h, m, r 1:1000 
#1649-1 Rabbit- mono Epitomics Smad1 h,m 1:1000 
H6908 Rabbit Sigma HA h, m, r 1:1000 
Ab20346 Mouse- mono Abcam Vimentin h,m,r,chic
ken, 
dog,pig 
1:1000 
1880-1 Rabbit- mono Epitomics/Biom
ol 
pSmad3 (pS423/425) h,m 1:1000 
9664 Rabbit- mono Cell signaling cleaved Caspase3 h, m, r, 
monkey, 
dog 
1:500 
25280 Mouse-mono Santa cruz PCNA h, m, ra 1:1000 
GTX10841
7 
Rabbit-poly Genetex BMP-9 h, m, r 1:500 
ab12221 Rabbit-poly Abcam N-cadherin h, m, Ra, 
Chicken, 
Cow, 
Zebrafish 
1:1000 
2870 Rabbit-mono Cell signaling Bcl-2 h, m, r 1:1000 
    
Tab.2. First antibodies used for Western blot. 
           *h, human; m, mouse; r, rabbit; ra, rat. 
 
Secondary antibodies Company dilution 
Goat anti-mouse HRP Santa Cruz Biotechnology, California, USA 1:5000 
Goat anti- rabbit HRP Santa Cruz Biotechnology, California, USA 1:5000 
 
Tab.3. Horseradish peroxidase (HRP)-conjugated antibodies used for immunostaining. Dilutions of the 
antibodies were used according to instructions provided by the companies. 
 
      3.5.8. Immunodetection of proteins 
 
The blotting membrane was blocked with the blocking solution for 1 h at room temperature, 
followed by wash with TBST for 5 min 3 times. The membrane was incubated with the first 
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antibody at 4 ° C overnight. Afterwards, it was washed with TBST for 5 min 3 times. Then it 
was incubated with the certain secondary antibody for 1 h at room temperature. After being 
washed with TBST for 5 min 3 times, the membrane was incubated with ECL solution for 2 
min. Then the chemiluminescence was detected with a Fujifilms LAS 1000 image detection 
system.  
 
   3.6. Immunohistochemistry (IHC) 
 
      3.6.1. Deparaffinization 
 
Formalin fixed and paraffin embedded tissue sections were incubated at 60° C for 60 min.  
They were dewaxed with xylene for 5 min 3 times. 
 
      3.6.2. Dehydration 
 
Sections were incubated through descending ethanol: 100% ethanol for 5 min twice and 95% 
ethanol for 5 min once. 
 
      3.6.3. Rehydration 
 
Sections were incubated in distilled water 1 × 5 min, followed by being rinsed in PBS 1 × 5 
min. 
 
      3.6.4. Antigen demasking 
 
Sections were heated up to 95° C ( 2 - 3 min 200 W) in 10 mM EDTA pH 8, then 50 sec-off-
10 sec-on of the microwave were performed for 10 min. Then sections were cooled for 35 - 
40 min to reach a temperature of 37° C and washed with PBS 3 × 5min. 
 
      3.6.5. Blocking of endogenous peroxidase 
 
Tissues were covered with some drops of “Dual Endogenous Enzyme Block” in a humid 
atmosphere for 15 min. For some antibodies, additional blocking with 3% H2O2 was 
performed. 
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      3.6.6. Antibody incubation 
 
After sections were washed with PBS 3 × 5min, they were incubated with the diluted first 
antibodies at 4° C overnight. Afterwards, they were re-warmed at room temperature for 1 
hour. The corresponding secondary antibodies were added after washing the sections with 
PBS 3 × 5 min. 
 
First antibodies 
Cat. 
No 
Clonality Supplied 
by 
Antibody, epitope,lacation Species* Dilution 
1406-
1460 
Rabbit- 
mono 
AbD 
serotec 
BMP-9 h 1:400 
#9511 Rabbit- poly Cell 
signaling 
pSmad1 (Ser463/465)/Smad5 
(Ser463/465)/Smad8 (Ser426/428) 
h,m,r 1:100 
M0851 Mouse-
mono 
DAKO α-SMA h, m, r 1:500 
3195 Rabbit- 
mono 
Cell 
signaling 
E-cadherin h, m, dog 1:400 
ab1520
0 
Rabbit- poly Abcam desmin h, m, rat 1:100 
ab1773
2 
Rabbit-poly Abcam Snail h, m 1:1000 
2870 Rabbit-
mono 
Cell 
signaling 
Bcl-2 h, m, r 1:100 
9664 Rabbit-
mono 
Cell 
signaling 
cleaved caspase3 h, m, r, 
monkey, dog 
1:100 
 
Tab.4. First antibodies used for IHC staining. 
 
Second antibodies Company dilution 
Goat anti-mouse DAKO, Glostrup, Denmark A/S 1:200 
Swine anti-rabbit DAKO, Glostrup, Denmark A/S 1:200 
   
Tab.5. Secondary antibodies used for IHC staining. 
 
      3.6.7. Preparation and application of peroxidase substrate DAB 
 
1 tablet of DAB was dissolved in 15 ml 0.05 M Tris (hydroxymethyl) aminomethane, pH 7.6 
(keep in dark) which was filtered with filter paper. 12 µl H2O2 was added to the filtrate. 
Sections were washed with PBS 3 × 5 min and covered with 200 µl of the substrate. The color 
development was observed under the microscope (maximally incubation time: 10 min) and 
the reaction was stopped by immersing the sections in distilled water for 5 min. 
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      3.6.8. Counterstaining, clearing and mounting 
 
Sections were immersed in Mayers Hämalaun solution for several seconds and then rinsed 
with water for 10 min, followed by being dehydrated through ascending ethanol: 95% ethanol 
2 × 10 sec and 100% ethanol 2 × 10 sec. Clearing was performed in xylene 2 × 10 sec. Finally 
sections were mounted with malin oil and covered with glass. 
 
      3.6.9. Semi-quantitative analysis for IHC staining 
 
Staining scores were calculated according to the following method: positive cell number was 
graded as 0 - 4 (0, no positive cells; 1, less than 25% positive cells; 2, 25% - 50% positive 
cells; 3, 50% - 75% positive cells; 4, more than 75% positive cells). The intensity of positivity 
was graded as 1 - 3 (1, weak yellow staining; 2, strong and brown staining; 3, very strong and 
deep brown staining). The score was calculated according to this formula: grade of number × 
grade of intensity. According to the calculated score, the staining level was divided into 3 
levels: 0, no positive staining; 1+, score of 1 to 5; 2+, score of no less than 5.  
 
   3.7. Immunofluorescence (IF) 
 
      3.7.1. Preparation of cover slips and plating of the cells 
 
One cover slip per well was placed in a 12-well plate, which was exposed to UV light under 
the sterile hood for 1 h. Wells were washed once with HBSS before cell plating. Cell 
treatment was done at the indicated time point. 
 
      3.7.2. Fixation and permeabilization of cells 
 
Cell medium was removed and cells were washed twice with HBSS. Cells were incubated 
with 300 μl  4% PFA solution for 5 min. 4% PFA was discarded and cells were permeabilized 
with 300 μl permeabilization buffer for 5 min. After discarding the permeabilization buffer, 
cells were fixed with 2% PFA for 5 min. 2% PFA was removed and cells were washed once 
briefly with HBSS. Then the slides were dried. 
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      3.7.3. Incubation with primary antibody 
 
Cells were washed with HBSS 2 × 5 min, followed by 0.1% Tween20 solution 1 × 1 min. 
Then cells were blocked with the blocking solution for 1 h at room temperature. Cells were 
washed with 0.1% Tween20 solution 1 × 1 min. The cover slips were placed in the lid, which 
was then put in a humid chamber. The primary antibody solution was added onto the cover 
slips. Cells were incubated with the primary antibody at 4°C overnight. 
 
First antibodies 
Cat. No Clonality Supplied by Antibody Species* Dilution 
610181 Mouse- mono BD Biosciences E-cadherin h, m, r 1:200 
Ab20346 Mouse- mono Abcam Vimentin h, m, r, chicken, dog, pig 1:200 
 
Tab.6. First antibodies used for IF staining. 
 
      3.7.4. Incubation with secondary antibody 
 
The primary antibody solution was discarded. Cells were washed with HBSS 3 × 5 min and 
0.1% Tween20 solution 1 × 1 min. The secondary antibody diluted in blocking buffer was 
added onto the cover slips. Cells were incubated with it for 45 min at room temperature. 
 
Second antibodies Company dilution 
Goat anti-mouse Alexa488 Invitrogen 1:200 
Goat anti-rabbit  Alexa488 Invitrogen 1:200 
 
Tab.7. Secondary antibodies used for IF staining. 
 
      3.7.5. Nuclear staining  
 
The secondary antibody solution was discarded. Cells were washed with HBSS 3 × 5 min and 
with 0.1% Tween20 solution 1 × 1 min. DRAQ5 diluted in HBSS (1:5000) was added onto 
the cover slips. Cells were incubated for 5 min at room temperature. 
 
      3.7.6. Mounting 
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The cover slips were removed from the lid without washing steps. A drop of mounting 
medium was put on a clean slide and a cover slip was placed up-side-down into the mounting 
medium. The slides can be stored in the dark at -80°C for at least 2 weeks. 
 
   3.8. Detection of mRNA expression 
 
      3.8.1. Isolation of total RNA from monolayer cells 
 
RNA isolation was performed using the High Pure RNA Isolation kit from Roche according 
to the company’s instruction. After being washed with HBSS, cells cultured in 6-well plates 
were incubated with 400 μl lysis buffer for 1 min, following by 200 μl HBSS. Both the lysis 
buffer and HBSS were transferred into a fresh sterile eppendorf tube and vortexed vigorously 
for 50 sec, then they were pipetted into a spin column for adsorption. After centrifugation, 
followed by 3 washing steps, the RNA was eluted with elution buffer. RNA concentration and 
purity were determined using a spectrophotometer.  
 
      3.8.2. Isolation of total RNA from mouse liver tissue 
 
50 - 100 mg liver tissue was homogenized in 1 ml Trizol using an UltraTurrax (IKA, Staufen, 
Germany). This homogenate was centrifuged with 12,000 g for 10 min at 4°C. The 
supernatant was transferred to a fresh sterile tube. 200 µl isopropanol was added into 1 ml 
Trizol. The mixture was shaken vigorously for 15 sec,   incubated for 2 - 3 min at room 
temperature and centrifuged with 12,000 g for 15 min at 4°C. The aqueous phase was 
transferred into another fresh sterile tube. Then 500 µl isopropanol was added into 1 ml Trizol. 
The mixture was incubated for 10 min at room temperature and centrifuged with 12,000 g for 
10 min at 4°C. Afterwards, the supernatant was removed and 1 ml 75% ethanol was added. 
This mixture was centrifuged with 10,000 g for 5 min at 4°C and the supernatant was 
removed. 1 ml 75% ethanol was added and the mixture was centrifuged with 7,500 g for 5 
min at 4°C. The supernatant was removed and the pellet was dried for 5 - 10 min. The latter 
was dissolved in RNase/DNase free water, cooled on ice for 2 min. The RNA was purified 
with High Pure RNA Isolation kit from Roche according to the company’s instruction 
mentioned above. RNA concentration and purity were determined using a spectrophotometer.  
   
      3.8.3. Reverse transcription (RT) 
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Reverse transcription reaction was performed with the Reverse Transcription Kit from Roche 
by following the instruction manual. 1 µg total RNA was reversely transcribed into 20 µl 
cDNA, diluted with 60 µl d H2O and used for standard PCR. 
 
      3.8.4. Polymerase chain reaction (PCR) 
 
2 µl of cDNA was used in conventional PCR amplification to detect the expression of interest. 
Samples were initially denatured at 95°C for 5 min and then subjected to different cycles of 
amplification (detail in Tab.8.). PCR products were separated on 1.5 % agarose gels.  
 
Gene name Forward Reverse Size 
(bp) 
Snail AATCGGAAGCCTAACTACAGCG GTCCCAGATGAGCATTGGCA 147 
Collagen 
1a(2) 
GGCTTCCTGGTGAGAGAGG CCTCTCTTTCCTTCTTCACC 497 
human rS6 GACTGATACTACAGTGCCTC GTAGAAGCTCGCAGAGAGG 371 
mouse rS6 GTGCCTCGTCGGTTGGGAC GACAGCCTACGTCTCTTGGC 320 
desmin CTACTCGTCCAGCCAGCG CGGATCTCCTCTTCATGCAC 732 
ALK1 CTTCTCCTCGAGGGATGAAC TGGTTTGCCCTGTGTACCG 283 
ALK2 TTCCAGGTTTATGAGCAGGG CGTTTCCCTGAACCATGACT 537 
BMPRII GGACGCATGGAATATTTGCT TGGCTGCATTATCTTCCTCC 310 
ACVR2A CAAACTGGTGTTGAACCGTG GCACCAAGGAATAGAGCAGG 307 
Smad1 CCAGCCGCTATGAATGTGAC GAGTGAGGGTAGGTGCTGC 625 
Smad4 CCTCATGTGATCTATGCCCG CTGTGGACATTGGAGAGTTG 844 
Fibronectin GGTGTGGTCTACTCTGTGG CACACGTGCACCTCATCATG 540 
BMP-9 CTGAGCTCCGACTCTATGTC GTGCAATGATCCAGCTGTCC 581 
Collagen 1a1 GTCTCACTGGCAGTCCTGG TCTCCAGGAACACCCTGTTC 381 
α-SMA GTGCTGGACTCTGGAGATG CCACCGATCCAGACAGAGTA 575 
Id-1 CTGCTCTACGACATGAACGG CGTCGGCTGGAACACATGC 274 
 
Tab.8. Primer sequences used in the study. 
 
      3.8.5. Real-time quantitative PCR 
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Real-time quantitative PCR was done on the Sequence Detection System ABI Prism 7700 
(Applied Biosystems, Foster City, CA, USA,) and TaqMan® probes abd TaqMan Universal 
PCR Master Mix, No AmpErase UNG (Applied Biosystems, Foster City, CA, USA, Part No. 
4324018) were used according to the manufacturer’s instructions. Samples in triplicate were 
initially denatured at 50°C for 2 min and 95°C for 10 min and then subjected to 40 cycles of 
15 s at 95°C and 1 min at 60°C. PCR products were investigated with ABI Prim 7000 SDS 
software ® (Applied Biosystems, Foster City, CA, USA,). Expression levels of targeted genes 
were calculated with the comparative ΔΔCt evaluation method with PPIA as reference gene.  
 
Gene name Assay ID 
BMP-9 Mm00807340_m1 
Id-1 Mm00775963_g1 
PPIA Mm02342429_g1 
 
                            Tab.9. Real-time quantitative PCR gene expression assays used in the study. 
 
   3.9. Microarray analysis of gene expression 
 
Mouse primary hepatocytes were treated with BMP-9 (5 ng/ml) for 24 h and RNA isolated 
from 3 independent repetitions was collected and pooled, and was used for the microarray 
analysis. The gene expression was analyzed via moe430_2 microarrays (Affymetrix, Santa 
Clara, CA, USA). The array was scanned following the manual of the manufacturer. Raw 
values for fluorescence intensity were normalized via quantile normalization. Gene expression 
values were displayed after being converted to a log2 scale. Genes down-/up-regulated more 
than 1.4 fold were regarded as significantly changed. 
 
   3.10. Transwell assay 
 
The migration of HepG2 and HLE cells was detected in a modified 24-well transwell chamber 
(BD Biosciences, Heidelberg, Germany). In the upper chamber, 25,000 cells in 0.25 ml of 
serum-free culture medium were treated with BMP-9 (50 ng/ml). Medium with 10% FCS and 
with or without BMP-9 (50 ng/ml) was loaded in the lower wells serving as chemotactic 
stimulus. After 6 (HLE cells) or 24 (HepG2 cells) hours at 37°, the cells on the upper surface 
of the filter and the underside were trypsinized, washed with serum-free DMEM and 
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transferred to a 96-well flat bottomed plate, respectively. After centrifugation at 1,000 rpm for 
10 min, the supernatant was discarded and 40 ul buffer of the CellTiter-Glo
®
 Luminescent 
Cell Viability Assay (Promega, Mannheim, Germany) was added to each well. Luminescence 
was measured by the iControl1.6 program. The percentage of migrated cells was calculated. 
Each experiment was conducted in triplicate, and the mean ± SD was calculated.  
 
   3.11. In situ hybridization (ISH) (done by Shahrouz Ghafoory) 
 
      3.11.1. RNA isolation from target tissue and cDNA synthesis 
 
For human samples, RNA was isolated from HepG2 cells using NucleoSpin® TriPrep 
purification system (Macherey-Nagel, Düren, Germany). First-strand cDNA was synthesized 
with 3 μg total RNA, random hexamer primers and avian myeloblastosis virus (AMV) reverse 
transcriptase following the manufacturer’s protocol. 
     
For mouse samples, RNA was isolated from wild type male C57BL/6 mouse liver using 
NucleoSpin® TriPrep purification system. The following steps were the same as above 
described.  
 
      3.11.2. Primer design 
 
Primers were designed to contain a short terminal 5’ sequence followed by the sequence of 
SP6 or T7-RNA-polymerase promoter and the specific primer sequence of interested genes. 
The SP6 promoter was combined with the up-stream of the specific primer and the T7 
promoter with the down-stream of the primer. Then anti-sense cRNA probes were synthesized 
using T7-RNA-polymerase, and by SP6-RNA-polymerase yielded sense cRNA probes.  
The following primers were used 
 (H. BMP-9. SP6) 5’-
CAGTGAATTGATTTAGGTGACACTATAGAAGTGGAACAAGAGAGCGTGCTCAAG
AAGC-3’ and (H. BMP-9. T7) 5’-
CAGTGAATTGTAATACGACTCACTATAGGGAGACTCCTCCACCTCTCTAACTTCC
ATC-3’ (amplified fragment: 998-1820 nt of BMP-9 mRNA, GeneBank: NM_016204.1).  
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(M. Id1. SP6) 5’-
CAGTGAATTGATTTAGGTGACACTATAGAAGTGGTAATCGACTACATCAGGGACC
TGC-3’ and (M. Id1. T7) 5’-    
CAGTGAATTGTAATACGACTCACTATAGGGAGACAGAAACACGCGGGGTTGATT
AACC-3’ (amplified fragment: 338-739 nt of Id1 mRNA,  GeneBank: NM_010495.2) 
(M. BMP-9. SP6) 5’-             
CAGTGAATTGATTTAGGTGACACTATAGAAGTGCAGCCAAAAATGCTTACCAGGT
GGC-3’ and (M. BMP-9. T7) 5’- 
CAGTGAATTGTAATACGACTCACTATAGGGAGACAGCTCTCTGCACATCACCTGT
ATC-3’ (amplified fragment: 969-1720 nt of BMP-9 mRNA, GeneBank: NM_019506.4)     
(M. Albumin. SP6) 5’- 
CAGTGAATTGATTTAGGTGACACTATAGAAGTGCCTGCAACACAAAGATGACAA
CCCC-3’ and (M. Albumin. T7) 5’-
CAGTGAATTGTAATACGACTCACTATAGGGAGAGGGATCCACTACAGCACTTGGT
AAC-3’ (amplified fragment: 423-1559 nt of Albumin mRNA, GeneBank: NM_009654.3) 
(M. TβR-II. SP6) 5’-
CAGTGAATTGATTTAGGTGACACTATAGAAGTGCGTTCCCAAGTCGGATGTGGAA
ATGG-3’ and (M. TβR-II. T7) 5’-
CAGTGAATTGTAATACGACTCACTATAGGGAGAGAGAAGCGGCATCTTCCAGAG
TGAAG-3’ (amplified fragment: 407-756 nt of TβR-II mRNA, GeneBank: NM_009371.3)  
                                   
      3.11.3. Template synthesis by PCR 
 
PCR templates were acquired as follows: 1 μg cDNA, 1 μl deoxynucleotide triphosphates 
(dNTPs) 10 mM, 0.5 μl of DreamTaq 5 u/μl, 0.5 μl upstream (SP6) primer and 0.5 μl 
downstream (T7) primer (each 100 pmol/μl) in a total volume of 50 µl were used for the first 
PCR reaction. Standard PCR was performed with 2 min at 95°C, preceding 30 cycles with 30 
sec at 95°C, 2 min at 60°C and 1 min at 72°C.  
     
All the products except a separate small aliquot of the reaction were run on a 1% agarose gel 
without ethidium bromide. And this ethidium bromide-stained lane for the small aliquot with 
a suitable size standard was cut from the gel and stained to visualize the PCR reaction 
products. The position of the PCR fragment in the ethidium bromide-stained lane was 
measured and a ruler was used to define the position of the corresponding non-stained gene 
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specific cDNA PCR fragments. They were excised from the gel and extracted with a DNA 
extraction kit. The remaining gel may be stained to confirm that the band was correctly 
excised.   
     
The purified PCR fragments were then used for a second PCR amplification in a larger 
volume (e.g. 400 μl) according to the protocol described above, as well as several parallel 
PCR reactions of 50 μl. The resulting template PCR fragments were purified and concentrated 
with phenol-chloroform extraction and ethanol precipitation. The concentrated PCR 
fragments were purified again using agarose (1%) gel electrophoresis, the appropriate PCR 
fragments were excised and finally purified with a DNA extraction kit. The purified PCR 
fragments were utilized directly for in vitro transcription of the cRNA probes. 
 
      3.11.4. ISH riboprobe synthesis 
 
Digoxigenin (DIG) labeled cRNA was synthesized with 1 μg of probe template DNA of 
interested genes, 1 μl DIG 10x nucleotide mix, 1 μl SP6 or T7 RNA polymerase (20 u/µl) in a 
total volume of 10 μl. SP6 RNA polymerase was used for sense labeled cRNA preparation 
and T7 RNA polymerase for anti-sense labeled cRNA preparation. The labeled cRNA probes 
were precipitated with absolute ethanol and the pellet was dissolved in 50% Formamide / 2x 
SSC. 
 
      3.11.5. Preparation of tissue sections 
 
Pieces of mouse and human tissue were rapidly rinsed in PBS and fixed with 4% PFA at 4°C 
overnight. Fixed tissue was washed with PBS, dehydrated with 50%, 70%, 96% and 100% 
ethanol, immersed in xylene twice and embedded with paraffin. Sections were cut at a 
thickness of 4 μm and placed on poly-L-Lysine-covered slides.  
     
Paraffin sections were deparaffinized and rehydrated in xylene 2 × 7min, xylene/ethanol 1 × 2 
min, ethanol in decreasing concentration 2 × 2 min followed by PBS. Sections were then 
incubated with 20 μl/ml proteinase K for 8 min at 37°C, with 0.2% glycin for 6 min and post-
fixed with 4% PFA supplemented with 0.2% glutaraldehyde for 20 min. 
 
      3.11.6. ISH 
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After ‘post-fixation’ in 4% PFA-glutaraldehyde, slides were washed twice with PBS. Liver 
sections were then covered with hybridization mix (5 ml Formamid, 2.5 ml 20x SSC, pH 4.5, 
100 mg Boehringer Block, 2 ml Milipore-Water, 100 μl 0.5 M EDTA, pH 8.0, 100 μl Tween 
20 (10%), 100 μl 10% CHAPS, 4 μl Heparin (50 mg/ml), 200 μl tRNA (50 mg/ml) and 
prehybridized for 1h at 69°C. The hybridization mix was denatured at 95°C for 5 min and 
chilled on ice immediately before it was added to tissue sections. After prehybridization, 
specific probes were added to 200 - 300 μl hybridization mix in order to obtain a final 
concentration of 2 ng/μl. The probe containing the hybridization mix was denatured at 95°C 
for 5 min and cooled on ice. For hybridization, the hybridization mix was added to tissue 
sections, which were incubated overnight at 70°C. Afterwards, tissue sections were washed 
with 2x SSC, incubated with 50% Formamide/ 2x SSC 30 min at 65°C, and washed with PBS 
containing 0.1% Tween at room temperature. Then the sections were incubated for 1 h at 
37°C with 1% blocking reagent in PBS (B- Block) and 2 h at 37°C with alkaline phosphatase-
coupled anti-digoxigenin antibody diluted 1:1000 in B-Block. Excess antibody was removed 
by washing for 2 × 8 min with PBS plus 0.1% Tween, then sections were incubated for 10 
min in NTM Buffer. Color development was performed at 37°C overnight in NTM buffer 
with NBT/BCIP 20 μl/ml. Staining was stopped by a 10 min-wash with PBS and slides were 
mounted with Aquatex. 
     
For double staining, after the washing step, the slides underwent another fixation with 4% 
PFA/PBS for 10 min at room temperature followed by washing 3 times with PBS plus 0.1% 
Tween. Afterwards, they were incubated with 1% blocking buffer for 1 h and with alkaline 
phosphatase-coupled anti-fluorescein antibody diluted 1:1000 in B-Block. Excess antibody 
was removed by washing 5 min × 3 with PBS plus 0.1% Tween, then sections were incubated 
for 10 min in NTM Buffer. Color development was performed at 37°C overnight in NTM 
buffer with INT/BCIP 7.5 μl/ml. Staining was stopped by a 10 min-wash with PBS and slides 
were mounted with Aquatex. 
 
      3.11.7. Semi-quantitative analysis of ISH results 
 
For the semi-quantitative assessment of ISH staining, staining scores were calculated with the 
following method: positive cell number was graded as 0 - 4 (0, no positive cells; 1, less than 
25% positive cells; 2, 25% - 50% positive cells; 3, 50% - 75% positive cells; 4, more than 
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75% positive cells). The intensity of positivity was graded as 1 - 3 (1, weak purple staining; 2, 
strong and purple staining; 3, very strong and deep purple staining). The score was calculated 
according to this formula: number × intensity. According to the calculated score, the staining 
level was classified into 3 levels: 0, no positive staining; 1+, score of 1 to 4; 2+, 5 and more.  
 
   3.12. Tissue specimens 
 
A total of 41 cases diagnosed as primary HCC from the surgical files in the Eastern 
Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China        
were enrolled in this study. The diagnosis was determined according to the UICC TNM 
classification of primary liver cancer, 6th edition (Sobin, 2002). 39 of them (95.12%) were 
HBsAg-positive. The study protocol conformed to the ethical guideline of the Declaration of 
Helsinki (1975). The study was approved by the ethics committee of the Second Military 
Medical University, Shanghai, China. All patients provided an informed consent. 
 
   3.13. Caspase3 assay 
 
      3.13.1. Preparation of cell lysates 
 
Cell apoptosis was induced in 12-well plates after treatment with TGF-β1 and/or BMP-9 for 
72 h at 37°C. Medium was removed and cells were washed with HBSS twice, which was 
sucked off later. 80 μl lysis buffer was added to each well and the cells were scratched off. 
Cell lysates were centrifuged at 13,000 rpm for 5 min at 4°C. Then the supernatant was 
transferred to a fresh tube and put on ice for immediate assay. The experiments were 
performed in triplicates. 
 
      3.13.2. Measurement of protein concentration 
 
The protein concentration was used to normalize the obtained data from the ELISA reading. It 
was done with the method described in the part of Western blot. 
 
      3.13.3. Measurement of Caspase3 activity 
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30 μl of the samples were transferred to each well of a 96-well plate (flat bottom white). 
Duplicates were performed for each sample. 70 μl of the assay buffer was added to each well. 
Then the plate was pre-incubated at 37°C for 10 min to allow enzyme interaction. The 
reaction was started when 10 μl of caspase3 substrate was added to each well and mixed 
gently by shaking. The plate was covered and incubated at 37°C for 60 min. The fluorescence 
(excitation 400 nm; emission 505 nm) was measured.  
 
   3.14. in vitro cell proliferation assay 
 
1×10
4
 LX-2 cells were pleated in a 6-well plate. BMP-9, TGF-β1 and PDGF were diluted in 
medium with a final concentration of 5 ng/ml, 5 ng/ml and 20 ng/ml, respectively. After 
serum starvation overnight, LX-2 cells were incubated with BMP-9, TGF-β1 or PDGF for 72 
h. Fresh medium with stimulation was changed every 24 h. After 72 h stimulation, cells were 
trypsinized, stained with trypan blue and counted with a Neubauer improved counting 
chamber (Biochrom, Berlin, Germany). Every condition was performed in triplicate and the 
experiment was repeated three times.  
 
   3.15. Microscopy 
 
      3.15.1. Phase contrast microscopy 
 
Phase contrast images were achieved with a Leica IPB microscope and a Leica DC500 
camera (Leica Microsystems, Wetzlar, Germany). Leica IM50 software was applied to 
acquire images. 
 
      3.15.2. Confocal microscopy 
 
Confocal scanning was performed with a Leica laser scanning spectral confocal microscope, 
model DMIRE2 equipped with an HCX PL Apo 40 ×/1.32 numeric aperture oil objective 
(Leica Microsystems, Wetzlar, Germany). Excitation was obtained with an argon laser which 
emits at 488 nm, a krypton laser at 568 nm and a helium/neon laser at 633 nm. Images were 
processed by a TCS SP2 scanner and Leica confocal software (version 2.5) (Leica 
Microsystems, Wetzlar, Germany). 
 
 56 
   3.16. Statistical analyses 
 
The association between immunohistochemical staining levels and clinicopathological 
features was evaluated with kendall-tau rank correlation analysis in SAS version 9.2 (Cary, 
NC, USA).  (done by Dr. Li Li) 
 
Student’s t-test was used to analyze the result of the migration assay. Error bars were the 
standard error of the mean. P<0.05 was considered statistically significant. 
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4. Results  
 
    (will be partially published in Breitkopf-Heinlein et al., submitted to Hepatology and 
Li et al., submitted to Oncogene) 
 
Part I  
 
Activation of the BMP-9/Smad1 signaling pathway in acute carbon 
tetrachloride-induced mouse liver injury in vivo and its potential functions 
in hepatocytes and hepatic stellate cells in vitro   
 
   4.1. Acute CCl4-induced liver injury is established in Balb/c mice 
 
Acute carbon tetrachloride (CCl4) intoxication led to necrosis of pericentral hepatocytes 
within 24 h which peaked at day 2 when serum ALT, AST and LDH levels were maximally 
elevated (Fig. 9 A, B) implicating serious liver damage. Subsequently a resolution of the 
necrotic damage occurred and at day 6 liver histology was almost recovered to the normal 
appearance. Serum markers for damage returned to low levels already on day 3 (Fig. 9 A). HE 
stainings demonstrated that within the pericentral area necrosis and inflammation occurred at 
day 1 and maximally at day 2, which was consistent with the elevation of the plasma enzymes 
(Fig. 9 B). Albumin is a specific marker for hepatocytes. Its synthesis and excretion is one of 
the important functions of hepatocytes (Schwarz et al., 1986). In the damaged area, the 
intensity of the positive signal of albumin mRNA as determined by ISH was largely reduced, 
especially at day 3 the damaged pericentral area could be clearly determined by its almost 
negative staining for albumin in hepatocytes (Fig. 9 C).  
     
This canonical acute liver injury model was used to investigate Smad1 activation, α-SMA, 
desmin, cleaved caspase3, BMP-9 and Id-1 expressions and their localizations within the liver 
tissue.  
 
A 
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B 
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Fig.9. Typical characteristics of the acute CCl4 mouse model for liver injury. A, Serum ALT, AST and LDH 
levels at the indicated time points after CCl4 application. B, HE staining showed transient necrotic damage. P, 
portal area; CV, central vein. Magnification, 10×. C, In situ hybridization of albumin mRNA. Magnification, 
10×.  
 
      4.1.1 Expressions of BMP-9 and pSmad1 are increased after CCl4 intoxication  
 
At the protein level, BMP-9 expression was significantly increased at day 3, which went 
down at day 6 (Fig. 10 A). From ISH, positive signal of BMP-9 mRNA existed in the 
cholangiocytes of the normal control liver (Fig. 10 D). After liver injury, BMP-9 mRNA 
expression was increased and positive signal could also be observed in hepatocytes. 
Especially at day 3, in the pericentral area, BMP-9 positive staining was observed (Fig. 10 D). 
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Interestingly, with real-time quantitative PCR BMP-9 mRNA increased very rapidly, within 3 
h after CCl4 injection (Fig. 10 B). This first, transient induction was followed by an up-
regulation of the BMP-9 target gene Id1 on the mRNA level (Fig. 10 C). At day 3 to 6 BMP-9 
mRNA expression increased again, but without a corresponding up-regulation of Id-1, 
implying that there exists a fine-tuned schedule of BMP-9 expression upon liver damage.  
     
By Western blot analyses, an increase of phosphorylated Smad1 appeared as early as 3 h after 
CCl4 application. This level of pSmad1 was reduced at day 1, but was still elevated until at 
least day 6 compared to normal livers (Fig. 10 A). From 3 h to day 3, within the lobule, 
intensities of pSmad1 immunostainings decreased gradually from the central vein to the portal 
area. At 3 h and 6 h, positive staining was mainly localized in hepatocytes and it was negative 
in sinusoidal cells. But from day 1 to day 3, besides positivity in hepatocytes, there was also 
positive staining in sinusoidal cells, most likely Kupffer cells, endothelial cells and hepatic 
stellate cells. In the pericentral area, positive staining was localized to the nucleus as well as 
cytoplasm of damaged hepatocytes. Furthermore, positivity could be observed in infiltrating 
cells, probably proliferating, activated HSCs. At day 6, when the liver nearly recovered to the 
normal status, only very weak pSmad1 expression was observed (Fig. 10 E). These data 
indicate that BMP-9/Smad1 signaling is activated upon CCl4-induced liver injury. 
 
A 
 
 
B                 
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Fig.10. Expression of BMP-9 and pSmad1 in response to CCl4-mediated liver injury. A, Western blots against 
BMP-9 and pSmad1 with GAPDH as a loading control. B, Real-time PCR analysis of BMP-9 expression. PPIA 
was used as internal control. C, Real-time PCR analysis of Id-1 expression. PPIA was used as internal control. D, 
In situ hybridization using BMP-9 cRNA as probes (positive staining = dark purple). Magnification, 10×. E, 
Immunohistochemistry (IHC) for pSmad1 using DAB (reddish brown color). Magnification, 10×.   
 
      4.1.2 BMP-9 and Id-1 are increased in the pericentral area   
 
At day 3 after CCl4 intoxication, expression of albumin in hepatocytes within the pericentral 
area was largely decreased compared to the remaining area (Fig. 11 A), meaning that due to 
processes of necrosis and/or apoptosis hepatocytes in this area showed reduced functionality.    
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ISH staining of serial sections showed that at day 3 in the pericentral area BMP-9 as well as 
its target gene, Id-1 was increased, implying that the BMP-9/Smad1 pathway was activated 
(Fig. 11 A, B). This could be further proven by the double staining for BMP-9 and Id-1 which 
demonstrated that BMP-9 and Id-1 co-localized in the pericentral area (Fig. 11 C). 
Interestingly, TβR-II was highly expressed in hepatocytes outside the pericentral area. 
However, inside the pericentral area, just like albumin its expression was lower (Fig. 11 A, B). 
These patterns of expressions imply that activation of BMP-9 and TGF-β1 signalling during 
wound healing processes in the liver is restricted to non-overlapping regions, pointing to 
differential functions of these cytokines. 
    
A 
 
                 
B        
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Fig.11. Localization of BMP-9, TβR-II and Id-1 in response to 
CCl4-medicated liver injury at day 3. A, In situ hybridization was 
performed using albumin, TβR-II, Id-1 and BMP-9 cRNA as 
probes with serial sections. Magnification, 10×.  B, Higher 
magnification of the indicated pericentral area in A is displayed. 
Magnification, 40×. C, Co-staining of Id-1 and BMP-9 by ISH. 
The purple color indicated BMP-9 mRNA expression and the red 
Id-1 mRNA expression. Magnification, 20× and 40×. 
 
      4.1.3 Apoptosis of hepatocytes is increased after CCl4 intoxication in mice 
 
Cell apoptosis is indispensable for tissue self-renewal. In the control normal livers, there was 
slight positivity of the apoptosis marker, cleaved caspase3, which was detected by IHC as 
small granules within the cytoplasm of a few hepatocytes. Starting already at 3 h after CCl4 
intoxication its staining intensity was increased, but was limited to the pericentral area, 
reaching a peak at day 3. Simultaneously, the size of the positive granules reached its 
maximal at day 3. At day 6, staining almost disappeared and its expression pattern was similar 
to that in the control liver (Fig. 12 A).  
 
Time-dependent changes of caspase3 activation could not be confirmed using total liver 
lysates in Western blot analysis but a constant increase compared to the control normal liver 
was always detected (Fig. 12 B). 
 
Intriguingly, at day 3 in the pericentral area both cleaved caspase3 and pSmad1 were 
expressed in hepatocytes (Fig. 12 C), suggesting pSmad1 signaling was involved in 
hepatocyte apoptosis in vivo.  
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Fig.12. Localization and expression of cleaved caspase3 in the response to CCl4-mediated liver injury. A, IHC 
was performed for cleaved caspase3. Magnification, 10×. B, Western blot for cleaved caspase3 during the time 
course. C, Co-localization of pSmad1 and cleaved caspase3 at day 3 is shown by IHC. Arrow, positive staining. 
Magnification, 10× and 40×.  
 
      4.1.4. CCl4 intoxication in mice leads to activation and increased proliferation of 
HSCs  
 
During this pathological process of CCl4 intoxication, desmin, a widely used marker for HSCs 
(see also Fig. 21 B), which are located in the Disse space of the liver, was positively stained 
within the pericentral area at day 1, indicating that HSCs migrated to the area of damage and 
started to proliferate. Desmin expression in this area kept being increased until day 3 (Fig. 13 
A). α-SMA, a marker especially for activated HSCs, was slightly expressed within the 
pericentral area at day 1, but increased strongly at day 3 and reduced again at day 6 when liver 
repair after CCl4 injury was almost achieved. No positive staining against α-SMA could be 
observed outside the pericentral area (Fig. 13 B). This suggests that at day 3 proliferation and 
activation of HSCs reached a peak after a single CCl4 insult. 
     
As mentioned above, at day 3, besides expression of α-SMA and BMP-9 in the pericentral 
area, pSmad1 expression was also increased (Fig. 13 C). In this area, positive pSmad1 
staining was observed not only in damaged hepatocytes with disappeared nucleus and the 
nuclear of normal hepatocytes, but also in the nuclear of the infiltrating cells, most likely 
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aHSCs (Fig. 13 C). These results imply that BMP-9/Smad1 signaling might be involved in 
proliferation and activation of HSCs in vivo. 
 
A 
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Fig.13. Expression and localization of desmin α-SMA and pSmad1 in response to CCl4-medicated liver injury. A, 
IHC against desmin. Magnification, 10×.  B, IHC was performed for α-SMA. Magnification, 10×. C, Co-
localization of pSmad1 and α-SMA in serial sections at day 3 is shown by IHC. Magnification, 10× and 40×.   
 
   4.2. Effects of BMP-9 in primary mouse hepatocytes 
 
      4.2.1. BMP-9 reduces expression of PCNA 
 
TGF-β1 itself leads to hepatocyte apoptosis and cell growth arrest (Lee and Bae, 2002). 
PCNA is a reliable indicator for cell proliferation (Nolte et al., 2005). Like TGF-β1, BMP-9 
also reduced PCNA expression in mouse hepatocytes in vitro (Fig. 14).  
 
 
 
Fig.14. Both BMP-9 and TGF-β1 lead to reduced PCNA expression in mouse hepatocytes. GAPDH was used as 
a loading control. 
 
      4.2.2 BMP-9 alone does not induce strong apoptosis  
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From the in vivo acute CCl4 model, expression of BMP-9 mRNA was noticeably observed in 
the pericentral area at day 3 (Fig. 11 B). Furthermore, at the same time point in the same area 
there was significantly positive staining for the apoptosis marker, cleaved caspase3 (Fig. 12 
B). We therefore investigated whether BMP-9 induced hepatocyte apoptosis in vitro. From 
day 1 to day 2, BMP-9 alone did not induce obvious cell apoptosis in cultured mouse 
hepatocytes although appearance of cleaved caspase3 was slightly induced (Fig. 15 A, B). 
Compared with TGF-β1, a strong inducer of hepatocyte apoptosis, which promoted caspase3 
activity significantly, BMP-9 alone did not lead to strongly enhanced caspase3 activity (Fig. 
15 C). 
 
A 
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Fig.15. BMP-9 alone does not cause strong cell apoptosis in mouse hepatocytes.  A, Cell morphology upon 
stimulation of hepatocytes with either BMP-9 or TGF-β1. Magnification, 10×. B, Western blot showing that 
cleaved caspase3 was slightly up-regulated by BMP-9 stimulation. C, Caspase3 assay demonstrating no cell 
apoptosis by BMP-9 alone compared to TGF-β1 alone. The experiment was performed in duplicates and was 
repeated 3 times. 
 
      4.2.3. Co-stimulation of BMP-9 and TGF-β1 results in enhanced activation of 
caspase3  
 
As mentioned above, BMP-9 alone did not induce strong hepatocyte apoptosis, which is a 
well-described function of TGF-β1. However, reduced cell density could be observed after 
co-stimulation with TGF-β1 and BMP-9 (Fig. 16 A). In addition, cleaved caspase3 was 
largely up-regulated and Bcl-2, an anti-apoptotic marker was down-regulated when 
hepatocytes were treated with BMP-9 and TGF-β1 simultaneously (Fig. 16 B). These 
outcomes were dose-dependent for BMP-9. Furthermore, co-stimulation enhanced caspase3 
activity compared to TGF-β1 alone (Fig. 16 C). This indicates that BMP-9 enhances TGF-β1 
mediated hepatocyte apoptosis.   
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Fig.16. Co-stimulation of mouse hepatocytes with BMP-9 and TGF-β1 leads to enhanced cell death. A, Cell 
morphology on day 3 of culture. Magnification, 10×. B, Western blot showing that cleaved caspase3 was 
enhanced and expression of Bcl-2 was down-regulated by co-stimulation. GAPDH was used as a loading control. 
C, Caspase3 assay demonstrating enhanced cell apoptosis by co-stimulation of TGF-β1 and BMP-9 compared to 
TGF-β1 alone. The experiment was performed in duplicate and repeated 3 times. 
 
      4.2.4. BMP-9 facilitates the maintenance of an epithelial phenotype  
 
Primary hepatocytes de-differentiate when being cultured in vitro. Especially, when cells are 
treated with TGF-β1, the de-differentiation process is significantly enhanced, which is 
indicated by obvious reduction of E-cadherin (Caja et al., 2011a) and other changes in 
expression which correlate with EMT (Dooley et al., 2008). From the morphology with co-
stimulation (Fig. 16 A), we expected an EMT-enhancing function of BMP-9, but from the 
expression levels this was not supported: while BMP-9 alone did not influence E-cadherin and 
albumin expression in hepatocytes, it reduced the expression of N-cadherin, a mesenchymal 
marker (Fig. 17 A). Furthermore, TGF-β1 induced down-regulation of E-cadherin could be 
partially rescued by BMP-9 which was not dose-dependent for BMP-9 (Fig. 17 B, C). And N-
cadherin still could be largely reduced (Fig. 17 C). Therefore, BMP-9 may function in 
maintaining the epithelial character of primary mouse hepatocytes. 
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    Fig.17. BMP-9 promotes an epithelial expression pattern in mouse hepatocytes with or without co-treatment 
with TGF-β1. By Western blot analyses it was shown that A, BMP-9 alone reduced expression of N-cadherin 
and induced Smad1 phosphorylation from day 1 to day 3. B, TGF-β1 induced down-regulation of E-cadherin 
was partially rescued by BMP-9. C, BMP-9 down-regulated expression of N-cadherin with or without TGF-β1 
co-treatment. GAPDH or β-actin served as loading controls. 
 
      4.2.5. Microarray analysis of samples from mouse hepatocytes stimulated with BMP-
9 for 24 h  
 
To further investigate whether BMP-9 has other potential functions in the liver besides its 
possible roles in HSC activation and hepatocyte apoptosis, and to know which genes will be 
up- and down-regulated by BMP-9 in mouse hepatocytes, we performed a microarray analysis. 
Freshly isolated mouse hepatocytes were incubated with BMP-9 (5 ng/ml) for 24 h. 32 genes 
were up-regulated and only 4 genes were down-regulated by more than 1.4-fold (Tab. 10). 
Through classifying these genes, we can speculate that BMP-9 most likely participates in liver 
metabolism, such as iron metabolism, triglyceride metabolism and sugar metabolism (Tab. 
11).  
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Tab.10. Genes up- or down-regulated by ≥ 1.4-fold at 24 h after addition of BMP-9 (5 ng/ml) to primary cultured 
mouse hepatocytes. 
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Tab.11. The BMP-9 regulated genes were grouped according to their possible functions as described in the 
literature. 
 
   4.3. Effects of BMP-9 in primary mouse HSCs 
 
      4.3.1. BMP-9 is increasingly expressed during in vitro transdifferentiation of HSCs 
together with enhanced Smad1 activation 
 
Since we observed that BMP-9, pSmad1 and α-SMA were all expressed in the pericentral area 
of the liver at day 3 after acute CCl4 intoxication, and the main profibrogenic cell type of the 
liver is HSCs, we further investigated whether the BMP-9/Smad1 pathway was involved in 
the transdifferentiation of HSCs in vitro. During this process, fat droplets disappeared 
gradually and cells transdifferentiate into myofibroblasts which produced extracellular matrix 
proteins (Fig. 18 A). In parallel, BMP-9 was increasingly expressed with a peak at day 3 and 
day 5 at the RNA level (Fig. 18 B, C) and at day 7 on the protein level (Fig. 18 D). As for 
pSmad1 and total Smad1, their expressions were continuously increased from day 1 to day 7 
along with increased α-SMA and PCNA, typical markers for HSC activation and proliferation, 
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respectively (Fig. 18 D). This expression pattern in vitro points to a role of the BMP-9/Smad1 
signaling pathway during transdifferentiation and proliferation of mouse HSCs. 
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Fig.18. BMP-9 and pSmad1 are increasingly expressed during mouse HSC transdifferentitation in vitro. Mouse 
HSCs were isolated from C57BL/6 mice. Protein and RNA were harvested at the indicated time points. A, 
Morphological changes of mouse HSCs in vitro during the time course. Magnification, 20× . B, BMP-9 
expression was detected with RT-PCR. rS6 served as internal control. C, BMP-9 expression was detected with 
real-time PCR. PPIA served as internal control. D, Detection of BMP-9, PCNA, α-SMA, Smad1 and pSmad1 
protein expressions by Western blot of samples from days 1 to 7. β-actin was used as  loading control.    
 
      4.3.2. BMP-9 induces proliferation in a human HSC cell line (LX-2) 
 
To investigate whether BMP-9 can promote cell proliferation in HSCs, LX-2, a human HSC 
cell line was incubated with BMP-9 (5 ng/ml), with TGF-β1 (5 ng/ml) as a negative control 
and PDGF (20 ng/ml) as a positive control for 72 h. At the end point, cell number was 
determined. The result showed that BMP-9 induced proliferation of HSCs (Fig. 19).  
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Fig.19. BMP-9 induces cell proliferation in LX-2 cells. LX-2 cells were stimulated with BMP-9, TGF-β1 or 
PDGF for 72 h and cell numbers were determined. The experiment was performed in triplicates and repeated 3 
times. 
 
      4.3.3. Dorsomorphin (DM) inhibits BMP-9-induced Smad1 activation in primary 
HSCs and LX-2 cells 
 
BMPs transduce their signals via activation of a group of so called “type I receptors”. These 
Smad1/5/8 activating receptors include ALKs 1, 2, 3, 6 (Miyazono et al., 2010). DM 
specifically inhibits this group of receptors (Yu et al., 2008). Both hepatocytes and HSCs 
responded to rhBMP-9 with activation of Smad1 signaling. Accordingly, in HSCs, pSmad1 
induction by BMP-9 could be completely blocked by DM treatment in vitro (Fig. 20). 
Although TGF-β1 induced transient pSmad1 expression was also reduced by DM, its 
canonical signaling via Smad3 was not influenced. As expected, DM also inhibited 
phosphorylation of Smad1 by other BMPs (BMP-2 and -6 in this case) in LX-2 cells (Fig. 20 
D).  
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Fig.20. BMP-induced pSmad1 signaling is effectively blocked by DM in HSCs. Western blot analyses were 
performed and pSmad1 and pSmad3 were detected. Cultured primary “mHSC day 2” (A) “mHSC day 7” (B)  
treated with DM or DMSO 1 h before being treated with TGF-β1 or BMP-9 for another 1 h. C, A human HSC 
cell line, LX-2 cells were treated with DM or DMSO 1 h before being treated with TGF-β1 or BMP-9 for 
another 1 h. D, LX-2 cells were treated with DM or DMSO 1 h before being treated with TGF-β1, BMP-2 (20 
ng/ml), 6 (20 ng/ml) , 9 (5 ng/ml) for another 1 h. β-actin or GAPDH served as loading controls as indicated. 
 
      4.3.4. Smad1 pathway inhibition by DM significantly decreases gene expression of 
markers for HSC activation in vitro 
 
We then investigated whether Smad1 activity is required for transdifferentiation of HSCs in 
vitro. When the cells were plated in the presence of DM they did not activate at all. When DM 
was added 24 h after initial cell attachment and remained on the cells from day 1 to day 2 this 
already profoundly affected cell morphology and reduced expression of marker genes like -
SMA, desmin, Id-1, collagen I or fibronectin. Similar results were acquired when the cells 
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were cultured with DM from day 4 to day 6 (Fig. 21 A, B). These results imply that the Smad-
1 pathway is required for transdifferentiation and blocking it seemed to revert the fibrogenic 
phenotype of HSCs back towards a more quiescent appearance. Since BMP-9 is a strong 
inducer for Smad1 activation and DM can inhibit BMP-9/Smad1 pathway in HSCs, BMP-9 
might act as a profibrogenic factor during HSC transdifferantiation. However, since DM is not 
specific for BMP-9 it can at this stage not be excluded that any other BMP is also involved in 
this process. 
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Fig.21. HSC transdifferantiation is inhibited by DM. A, Cell morphology was altered by DM during the early 
stage as well as late stages of HSC transdifferentiation. Magnification, 20×. B, RT-PCR demonstrating that DM 
reduced expression of genes which are otherwise up-regulated during HSC activation (Collagen type I, desmin, 
α-smooth-muscle-actin, fibronectin and Id-1). rS6 served as loading control. 
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Part II  
 
BMP-9 induces epithelial-mesenchymal transition (EMT) in hepatocellular 
carcinoma (HCC) cells 
 
   4.4. BMP-9 expression and signaling in liver samples from HCC patients 
 
      4.4.1. BMP-9 is expressed in HCC tissue  
 
We analyzed BMP-9 mRNA and protein expression in 41 HCC tissues and 36 paired non-
cancer liver tissues from liver cancer patients by IHC and ISH, respectively. We found that 
BMP-9 protein and mRNA expression existed in all patients, although the expression levels 
strongly varied (Fig. 22 A, B). BMP-9 protein expression levels were higher in the cancer 
area as compared to “normal” liver tissue in 9/36 (25%) patients, whereas 21/36 (58.33%) 
displayed similar expression levels in both areas (Tab. 12). BMP-9 protein staining was found 
in cancerous regions and due to ISH data we can conclude that BMP-9 did not only bind to 
the outer surface of HCC cells, but that it was indeed also synthesized by them (Fig. 22 A, B). 
According to an evaluation system as indicated in materials and methods, mildly positive (1+) 
BMP-9 staining was observed in 25/41 (61%), and moderately to strongly positive (2+) 
staining was present in 16/41 (39%) cancer samples of the patients. In 27/41 (65.85%) 
patients, BMP-9 protein and mRNA expression level were consistent. In 7/41 (17.07%) 
patients, there were 1+ mRNA levels correlated with 2+ protein levels, whereas in another 
7/41 (17.07%) patients, it was the other way around. 
     
A comparison of BMP-9 protein expression with clinicopathological features of the 41 
investigated HCC samples demonstrated a significant association of BMP-9 protein 
expression with T stage (B = 0.381, P = 0.016) and Child Pugh score (B = -0.328, P = 0.04) 
(Tab. 13), indicating that high BMP-9 levels correlated with invasion of the tumor, but did not 
mirror the decrease of liver functionality. 
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Fig.22. BMP-9 is expressed in HCC. Immunohistochemical analysis of BMP-9 expression was performed in 
paraffin-embedded HCC tissues from liver cancer patients (n=41 for tumor area and n=36 for non-tumor area). 
A, Immunohistochemical staining for BMP-9 in tumor and paired non-tumor regions of livers from HCC 
patients (brown color) varied from case to case. The extent was determined as mild (1+) and moderate to strong 
(2+). T: cancer area; N: paired non-cancer area. Magnification, 40×. B, Detection of BMP-9 mRNA expression 
by ISH. ISH with sense probe for BMP-9 was performed as negative control. Magnification, 40×.  
 
 
 
Tab.12. BMP-9 protein expression in cancer area and paired non-cancer area in HCC in 36 patients. 
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Tab.13. Relationship between immunohistochemical expression of BMP-9 and clinicopathological factors in 
HCC in 41 patients. 
 
      4.4.2. BMP-9 expression is associated with increased pSmad1 and Snail and 
decreased E-cadherin levels in HCC 
 
The BMP/Smad1 signaling pathway has been regarded as a significant player participating in 
the progression of carcinoma (Li, 2008). Snail and E-cadherin, two well-known EMT markers, 
play crucial roles in carcinogenesis. Therefore we next examined BMP-9 down-stream 
signaling and features of EMT using antibodies for phosphorylated Smad1 (pSmad1), Snail 
and E-cadherin and associated their occurrence/expression with BMP-9 protein levels. In 
HCC patients with 1+ BMP-9 level, E-cadherin signals were stronger, while those of Snail 
and pSmad1 were weaker, as compared to liver cancer samples with 2+ BMP-9 levels (Fig. 
23 A).  
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A semi-quantitative analysis of the staining results indicates a significant correlation of BMP-
9 expression with increased activity of Smad1. Although expression of BMP-9 was positively 
related to Snail expression and reversely correlated to E-cadherin expression, this did not 
reach statistical significance (Fig. 23 B).  
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Fig.23. Expression of BMP-9 is associated with Smad1 phosphorylation, Snail and E-cadherin expression in 
HCC. Immunohistochemical analysis was performed in paraffin-embedded tissues of HCC (n=41). Additionally, 
BMP-9 mRNA expression was shown with ISH. A, At 1+ BMP-9 expression levels, pSmad1 staining was 
mildly positive, E-cadherin cell surface expression was present and positive Snail nuclear staining was lower 
compared to those samples having 2+ BMP-9 expression levels. Representative images are shown. 
Magnification, 40×. B, Immunohistochemical staining of pSmad1, Snail and E-cadherin in HCC cells was semi-
quantitatively evaluated in 3 grades (-, 1+, 2+) as described in the Materials and Methods, and the association 
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with BMP-9 expression was calculated, demonstrating that BMP-9 expression is significantly correlated with 
nuclear pSmad1, positively related to nuclear Snail reversely related to cell surface E-cadherin expression in 
HCC.  
 
   4.5. BMP-9 expression and signaling in HCC cell lines (HepG2 and HLE) 
 
      4.5.1. BMP-9 signaling is functional in HCC cell lines 
 
In order to learn more about BMP-9 signaling in HCC cells, we assessed whether BMP-
9/Smad1 signaling components are expressed in the well-established HCC cell lines, HepG2 
and HLE. These cells were originally derived from primary tumors (Aden et al., 1979; Dor et 
al., 1975). Histologically HepG2 are classified as a well-differentiated liver cancer cell line 
and HLE as an invasive HCC cell line, but commonly representing epithelial phenotype.  
     
BMP-type I and II receptors ALK1, ALK2, BMPRII, ACVR2A as well as Smads-1 and -4 
were expressed in both cell lines at different levels as determined by PCR (Fig. 24 A).  
    
To investigate whether expression of the receptors correlated with BMP-9 responsiveness of 
the cells, we treated them with rhBMP-9 (50 ng/ml) and examined Smad1 C-terminal 
phosphorylation.  Both HCC cell lines were responsive to rhBMP-9 even at concentration as 
low as 5 ng/ml. Smad1 phosphorylation occurred as early as 10 min after stimulation, lasting 
at least 72 h (Fig. 24 B, C).  
 
Taken together, these data indicate that the BMP-9/Smad1 pathway is functional in HCC cells 
in vitro with a prolonged instead of a transient response, which is in line with previous 
descriptions of Smad1 signaling participating in EMT (Xu et al., 2011).  
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Fig.24. BMP-9 induces Smad1 phosphorylation in HCC cells. A, Components of the Smad1 pathway were 
slightly or strongly expressed in HepG2 and HLE cells. B, Cells were untreated or treated with different 
concentrations of BMP-9 as indicated for 1 h. pSmad1 and total Smad1 were analyzed by Western blot. C, Cells 
were treated with 50 ng/ml BMP-9 for the indicated time points. β-actin was used as loading control.  
 
      4.5.2 BMP-9 promotes migration  
 
The immunohistochemical analysis of the patient samples shown above point to a correlation 
between BMP-9 and EMT in HCC. Since increased migration is a typical feature of EMT we 
performed Transwell assays using the two cell lines. Treatment with BMP-9 (50 ng/ml) 
increased cell migration in HLE and HepG2 cells by 2.38 and 3.72 fold, respectively (Fig. 25).  
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Fig.25. BMP-9 enhances cell motility in HLE and HepG2. HCC cell lines were plated into the Transwell 
chambers and treated or not with BMP-9 (50 ng/ml). At the end point of the migration assay, cells in the upper 
and lower chambers were trypsinized and transferred to a fresh 96-well flat bottom plate. ATP content, which 
correlates to cell number, was evaluated for migrated and non-migrated cells. *P<0.05, Student’s t-test was done 
to analyze statistical difference. Experiments were performed in triplicates and repeated three times.  The 
average ±SEM of all experiments is shown.  
 
      4.5.3. BMP-9 induces morphological changes typical for EMT  
 
We then investigated cell morphology and expression levels of EMT markers upon 
stimulation of the cells with BMP-9 for 72 h. Cell morphology displayed that BMP-9 led to 
some conversion of the cells from an epithelial to a fibroblastic cell morphology (Fig. 26 A). 
Although both the cell lines are considered to be of epithelial phenotype, stainings of fixed 
cells showed that basal E-cadherin expression was rather diffuse and not strictly localized to 
the cell membranes and the cell-cell contacts (Fig. 26 B, C). However, BMP-9 treatment 
reduced E-cadherin and increased Vimentin immunofluorescence (Fig. 26 B, C). 
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Fig.26. BMP-9 induces morphological changes of EMT in HCC cells. HLE and HepG2 cell lines were untreated 
or treated with BMP-9 50 ng/ml for 72 h after serum-starvation overnight. A, Mophological changes induced by 
BMP-9. Magnification, 20×. B, HepG2 cells and C, HLE cells were immunostained with anti-E-cadherin and 
anti-Vimentin antibodies. DRAQ5 was used to show nuclei (Scale was indicated in the image).  
 
      4.5.4. BMP-9 induces expression of EMT makers  
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In accordance with the fibroblastoid morphological changes, BMP-9 down-regulated E-
cadherin and induced Vimentin expression (Fig. 27 A). Snail, a key transcription factor 
responsible for the down-regulation of E-cadherin was significantly induced by BMP-9 at the 
RNA level (Fig. 27 B).  
     
Collectively, these results support the hypothesis that BMP-9 facilitates EMT and migration, 
and therefore eventually also metastasis of HCC cells. 
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Fig.27. BMP-9 induces expression of EMT markers in HCC cells. HLE and HepG2 cells were untreated or 
treated with BMP-9 50 ng/ml for 72 h after serum-starvation overnight. A, Western blots against E-cadherin and 
Vimentin. GAPDH served as a loading control. B, RT-PCR showing that BMP-9 induced Snail mRNA 
expression in both HCC cell lines.  
 
      4.5.5. BMP-9-induced down-regulation of E-cadherin is rescued by overexpression of 
dominant negative ALK1/2 (AddnALK1/2) 
 
Some studies using other cell types have demonstrated that ALK1 and ALK2 are BMP-9 
specific type I receptors (Luo et al., 2010). We used adenoviral infection to functionally link 
BMP-9 mediated signal transduction to down-regulation of E-cadherin in HCC cell lines. 
With overexpression of dominant negative forms of these receptors (AddnALK1/2), 
phosphorylation of Smad1 was blocked along with down-regulation of E-cadherin upon 
stimulation with BMP-9 (Fig. 28).  
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Fig.28. ALK1/2 is required for BMP-9 mediated E-cadherin expression. A, Scheme of the experimental setup for 
adenovirus infection. B, HepG2 cells were infected with either AdLacZ (infection control) or AddnALK1/2. 
Anti-pSmad1 immunoblots showing that Smad1 phosphorylation was blocked by AddnALK1/2 and down-
regulated E-cadherin induced by BMP-9 was rescued by AddnALK1/2. C, The same effects of AddnALK1/2 on 
HLE cells are shown.  
 
      4.5.6. Overexpression of constitutively active ALK1 down-regulates E-cadherin  
 
 96 
Furthermore, overexpression of constitutive active ALK1 (AdcaALK1) could mimic the 
function of BMP-9, leading to phosphorylation of Smad1 and down-regulation of E-cadherin 
(Fig. 29).  
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Fig.29. caALK1mimices BMP-9 mediated E-cadherin down-regulation in HCC cells. HCC cell lines were 
seeded in 6-well plates and infected with either AdLacZ or AdcaALK1 overnight followed by medium change. 
Cells were untreated or treated with BMP-9 (50 ng/ml ) for 72 h after serum starvation for 4 hs. A, HepG2 cells 
were infected with AdcaALK1. Anti-pSmad1 immunoblots showing that Smad1 phosphorylation was induced 
and E-cadherin was down-regulated by AdcaALK1. B, The same effects of AdcaALK1 on HLE cells are shown. 
      4.5.7. Overexpression of constitutively activate ALK2 down-regulates E-cadherin 
 
Since BMP-9 has also been described to signal via ALK2 in some cell types (Luo et al., 2010), 
constitutive active ALK2 (AdcaALK2) was used in our study. AdcaALK2 could also mimic 
the function of BMP-9, leading to phosphorylation of Smad1 and down-regulation of E-
cadherin (Fig. 30 A, B).   
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These results imply that BMP-9 induces an EMT response in HCC via signaling through the 
type I receptors ALK1 and/or ALK2.   
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Fig.30. caALK2 mimics BMP-9 mediated E-cadherin expression in HCC cells. HCC cell lines were seeded in 6-
well plates and infected with either AdLacZ or AdcaALK2 overnight followed by medium change. Cells were 
untreated or treated with BMP-9 (50 ng/ml) for 72 h after serum starvation for 4 hs. A, HepG2 cells were 
infected with AdcaALK2. Anti-pSmad1 immunoblots showing Smad1 phosphorylation was induced and E-
cadherin was down-regulated by AdcaALK2. B, The same effects of AdcaALK2 on HLE cells are shown. 
 
      4.5.8. Smad1 overexpression does not further enhance BMP-9 induced down-
regulation of E-cadherin  
 
Since BMP-9 signals via Smad1, we further studied whether over-expression of Smad1 could 
enhance the down-regulation of E-cadherin upon BMP-9 treatment in HepG2 and HLE cells. 
Though overexpression of Smad1 successfully increased Smad1 levels in HCC cells, without 
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additional application of BMP-9 this failed to activate Smad1 signaling and especially in 
HepG2 cells reduction of expression of E-cadherin was not massively enhanced by Smad1 
over-expression (Fig. 31 A, B).  
     
These results imply that availability of Smad1 protein is not the limiting factor in this context 
and that endogenous Smad1 levels seem to suffice for maximal BMP-9 responses. The results 
further demonstrate that there do not seem to be any Smad1 activating cytokines 
endogenously expressed in these cells because increased total Smad1 did not lead to any basal 
phosphorylation. The cell lines differ in this regard from the primary HCC cells in vivo which 
express BMP-9 by themselves as shown above. 
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Fig.31. Smad1 overexpression does not strongly enhance BMP-9 mediated E-cadherin down-regulation. HCC 
cell lines were seeded in 6-well plates and infected with either AdLacZ or AdSmad1 overnight followed by 
medium change. Cells were untreated or treated with BMP-9 (50 ng/ml) for 72 h after serum starvation for 4 hs. 
A, Western blot of lysates from HepG2 cells infected with AdSmad1. B, Western blot of lysates from HLE cells 
infected with AdSmad1. Β-actin was used as loading control. 
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5. Discussion 
 
BMPs are a subfamily of the TGF-β superfamily and its first member, TGF-β1, was originally 
described in 1983 (Assoian et al., 1983). TGF-β family members have been discovered to play 
important roles in various physiological and pathological conditions such as embryonic 
development, angiogenesis, fibrogenesis and carcinogenesis (David et al., 2009; Rahimi and 
Leof, 2007). BMP-9 was first described in the mouse liver by Celeste AJ, et al (Celeste, 1994). 
In healthy rat liver, only non-parenchymal cells, like HSCs and Kupffer cells are the main 
source of BMP-9, whereas hepatocytes were initially reported to be negative for BMP-9 
(Miller et al., 2000). In this study, the researchers used ribonuclease protection assay and 
Western blot to detect BMP-9 mRNA and protein expression in different liver cell types and 
whole liver lysates. At the RNA level they found BMP-9 expression in the whole liver lysates 
and in non-parenchymal cells. In contrast to this, at the protein level, BMP-9 expression was 
detected in non-parenchymal cells, but not in the whole liver lysates. In another study 
investigating mouse and human liver, cholangiocytes and hepatocytes were identified as 
major producers of BMP-9 (Bidart et al., 2012). These authors also detected BMP-9 
expression in whole liver lysates as well as different liver cell types including cholangiocytes, 
hepatocytes, hepatic stellate cells and hepatic sinusoidal endothelial cells at the RNA and 
protein levels, but here these were measured with real-time PCR and IHC. Their data are 
consistent at both levels and indicate that basal expression of BMP-9 exists in healthy liver. 
Furthermore, BMP-9 mRNA level in cholangiocytes is 6 times higher than in hepatocytes and 
nearly 100 times higher than in HSCs and hepatic sinusoidal endothelial cells (Bidart et al., 
2012). These results are mainly consistent with ours. With ISH we found a positive signal for 
BMP-9 mRNA in normal mouse liver which was located mainly in cholangiocytes, whereas 
in hepatocytes and other cell types, it was rather low or negative. Most likely, ISH is not 
sensitive enough to detect basal BMP-9 levels in these other cell types under healthy 
conditions. Bidart et al have recently reported that under physiological conditions, BMP-9 
circulates in inactive (40%) as well as active (60%) forms in plasma and the active form 
functions in endothelial cells to keep them in a resting state (Bidart et al., 2012). BMP-9 is 
one of the most potent BMPs inducing bone formation. Furthermore, it has been reported to 
function in hematopoiesis, glucose homeostasis, iron balance, angiogenesis, neuronal 
differentiation and carcinogenesis (Bessa et al., 2009; Chen et al., 2003; Suzuki et al., 2010; 
Truksa et al., 2006). Although liver has been identified as the dominant source of active BMP-
9 and Song et al reported that BMP-9 induces cell proliferation in primary rat hepatocytes 
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(Song et al., 1995), possible roles of this cytokine in various liver diseases have not been fully 
clarified. Therefore, in the present study potential functions of BMP-9 in the liver were 
investigated in vitro and in vivo.  
     
As canonical model for liver injury, acute intoxication with CCl4 was established in Balb/c 
mice. HE staining, ISH of albumin and serum levels of ALT, AST and LDH showed that in 
this model liver damage occurred rapidly in the pericentral areas with increased serum levels 
of liver enzymes at day 1 after CCl4 injection, reaching a peak at day 2. This result is 
consistent with previous reports (Taniguchi et al., 2004; Tsuchiya et al., 2007), and this model 
was therefore used for further experiments.  
     
During the process of acute liver damage and recovery, a special pattern for BMP-9 
expression appeared. In total liver lysates BMP-9 RNA was rapidly increased within 3 h after 
CCl4 injection followed by a transient reduction until day 3. At day 3, its expression reached 
another peak at both protein and RNA levels, implying that BMP-9 might be involved in the 
wound-healing process that is initiated upon acute liver damage in vivo. Interestingly, in the 
pericentral area where hepatocytes were seriously damaged, positive signal was observed in 
hepatocytes when BMP-9 expression increased after CCl4-mediated liver injury. Furthermore, 
at day 3 BMP-9 and its main target gene, Id-1 were co-localized. To our knowledge, we show 
for the first time that during liver recovery, BMP-9 expression is induced which implies that 
this cytokine is involved in liver damage and/or liver regeneration processes. Because BMP-9 
improves glycemia in diabetic mice, Sosa I et al hypothesized that BMP-9 has a certain 
potential regenerative role in the liver and they also describe expression of BMP-9 in the 
Space of Disse (Sosa et al., 2011). However, nothing was reported yet about BMP-9’s 
possible role in liver regeneration. 
     
After CCl4 insult, the BMP-signal transducer, Smad1 was also increasingly activated. 
Phosphorylated Smad1 appeared mainly in hepatocytes already at 3 h after CCl4 application 
with a transient reduction at day 1, but remaining still higher than that in normal mouse liver. 
This result is in line with data from Ryusuke Nakastsuka et al, who also found rapid pSmad1 
expression at 3 h post CCl4-mediated injury in rats. They show that induction of pSmad1 
precedes an increase of BMP-2, another Smad1 inducer and conclude that this first increase of 
pSmad1 must be induced by proteins other than BMP-2 (Nakatsuka et al., 2007). In our study, 
the pSmad1 expression pattern, including very early time-points, matched well with BMP-9 
 101 
mRNA up-regulation. Therefore, it seems reasonable to conclude that BMP-9 is one of the 
candidates responsible for early activation of the Smad1 pathway after liver injury. Of course 
participation of other BMPs like BMP-2 can, especially at later time-points, not be excluded. 
From day 1 to day 3, positive staining against pSmad1 was seen not only in hepatocytes, but 
also in sinusoidal cells. In damaged hepatocytes of the pericentral area positivity was located 
in both the cytoplasm and nucleus. At day 3, positivity was additionally observed in 
infiltrating cells, probably proliferating activated HSCs. At the same time, Id-1 expression 
reached a peak. Id-1 up-regulation is reported to be directly mediated by the Smad1 pathway 
in HSCs, and Id-1 is involved in transdifferentiation of HSCs. Furthermore, in the chronic 
CCl4 model, phosphorylation of Smad1 correlates with up-regulation of Id-1 in vivo 
(Wiercinska et al., 2006). According to these expression patterns and localizations of BMP-9, 
pSmad1 and Id-1, and the importance of activated HSCs to liver regeneration and recovery 
(Iredale, 2001), we speculate that in the acute CCl4 model Id-1 is at least to some extent up-
regulated by the BMP-9/Smad1 pathway and that this pathway takes part in acute liver 
regeneration/wound-healing processes.  
     
When BMP-9 expression was significantly increased at day 3, within the pericentral area 
some hepatocyte apoptosis occurred. Apoptosis is an important type of cell death to terminate 
excessive or dangerous cell growth during organ evolution, remodeling of tissues and so on 
(Lockshin and Zakeri, 1990). On the other hand cell apoptosis is indispensable for tissue self-
renewal. Jialan Shi et al have found that large numbers of hepatocytes perform apoptosis 
induced by CCl4 intoxication and apoptosis of hepatocytes is increased at 3 h and peaked at 6 
h after CCl4 intoxication in rats. Furthermore, the percentage of apoptotic ballooned cells is 
increased until day 3 (Shi et al., 1998). Similar results could be achieved in our mouse model. 
Compared to the normal liver, the expression pattern of the apoptosis marker, cleaved 
caspase3 experienced significant change after CCl4 intoxication, and especially at day 3, the 
quantity of cleaved caspase3 was maximal as determined by IHC. Because BMP-9, pSmad1 
as well as cleaved caspase3 localized in the pericentral area at day 3, we investigated if BMP-
9 might induce hepatocyte death via apoptosis. When isolated primary mouse hepatocytes 
were stimulated with BMP-9 alone, we did not observe strong BMP-9-induced apoptosis. We 
therefore looked at a possible cross-talk of BMP-9 with known apoptosis-inducing factors like 
TGF-β1. 
      
TGF-β1 has been proven to trigger hepatocyte apoptosis in the liver in vitro as well as in vivo 
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(Oberhammer et al., 1992). In the CCl4-mediated liver injury mouse model, TGF-β1 mRNA is 
increased, arriving at a peak on day 1 and remaining at this high level at least until day 3 
(Hellerbrand et al., 1999). The mRNA levels of TGF-β1 receptors are decreased in rat 
hepatocytes from 12 h to 48 h, but recover at 72 h after CCl4 treatment and in HSCs their 
levels do not change (Date et al., 1998). In our stainings with serial sections, at day 3 BMP-9 
and Id-1 were highly expressed in the pericentral area whereas TβRII and albumin were 
comparably low here and higher outside the pericentral area. However, TβRII expression was 
still present within the pericentral area. Hence we expect that although there seem to be 
diverse patterns of activity of the BMP- vs. the TGF-β pathway in the different areas in vivo, 
the BMP-9/Smad1 pathway might still synergize with the TGF-β1 pathway in the pericentral 
area or at the borders of these areas mediating for example apoptosis of selected hepatocytes. 
Furthermore, expression of cleaved caspase3 was also increased in the pericentral area at day 
3. Interestingly, we found that combined stimulation of cultured hepatocytes with TGF-β1 and 
BMP-9 led to enhanced presence of cleaved caspase3 along with down-regulation of Bcl-2 
expression, the latter one being an anti-apoptotic factor and involved in TGF-β-triggered 
apoptosis (Motyl et al., 1998; Teramoto et al., 1998). This TGF-β1 enhancing effect of BMP-9 
on apoptosis was dose-dependent. These observations suggest that even though BMP-9 alone 
does not induce apoptosis, it synergizes with TGF-β1 in this regard. TGF-β1, activin A, TNF 
and CD95 ligand have as well been demonstrated to induce apoptosis in the liver (Schulte-
Hermann et al., 1997), it still requires further investigation to clarify whether BMP-9 also has 
synergistic effects with these factors to facilitate apoptosis in hepatocytes. In some liver 
cancer cells, like Hep3B, Huh7, SNU449 and PLC/PRF/5, TGF-β1 has also been shown to 
induce apoptosis (Caja et al., 2011b). If BMP-9 synergizes with TGF-β1 in these cells too, this 
might provide a new option for BMP-9 as an enhancer of TGF-β1-induced apoptosis in liver 
cancer cells which could contribute to possible cancer treatment options.  
     
We further investigated the molecular mechanism underlying BMP-9’s enhancing effect on 
TGF-β1-induced hepatocyte apoptosis. Irena CC et al have demonstrated that in hepatocytes, 
TGF-β1-induced expression of the NADPH oxidase NOX4 is necessary for induction of 
apoptosis (Carmona-Cuenca et al., 2008) and in endothelial cells BMP-4 induces apoptosis 
via NOX4 dependent ROS production and ROS-dependent p38 and JNK activation leading to 
caspase3 activation (Tian et al., 2012). From our microarray data, we can see that NOX4 was 
also up-regulated by BMP-9 in hepatocytes. This may be a possible explanation for the 
enhanced caspase3 activity and cell death by co-stimulation of BMP-9 and TGF-β1. Another 
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reason may be that BMP-9 facilitates to keep the epithelial phenotype of hepatocytes and 
epithelial cells are known to be more sensitive to TGF-β1-induced apoptosis than 
mesenchymal cells. During in vitro hepatocyte culture, hepatocytes undergo dedifferentiation 
and loose there epithelial phenotype (Dooley et al., 2008; Elaut et al., 2006). Liver cells 
undergoing EMT acquired enhanced resistance to apoptosis, most likely owing to the 
increased expression of Snail (Vega et al., 2004). On the other hand, down-regulation of Snail 
promotes the apoptotic effects of TGF-β1 on liver cells (Franco et al., 2010). We found in the 
present study that BMP-9 enhanced expression of epithelial marker proteins like E-cadherin 
in primary hepatocytes while down-regulating the mesenchymal marker N-cadherin. BMP-9 
even partially reverted TGF-β1-mediated down-regulation of E-cadherin implying that it 
antagonizes TGF-β1-mediated EMT to some degree. Whether this indeed represents the 
apoptosis-enhancing mechanism described above deserves further exploration.  
     
In our study, we did not see cell proliferation induced by BMP-9 in primary mouse 
hepatocytes. In addition, PCNA, a cell proliferation marker was reduced by BMP-9 implying 
that BMP-9 acts anti-proliferative on primary hepatocytes. This differs from the data by Song 
et al. who reported that BMP-9 leads to increased cell proliferation in primary rat hepatocytes 
and HepG2 cells (Song et al., 1995). However, this study also showed that only sub-confluent 
primary rat hepatocytes exhibit some proliferative response to rhBMP-9, confluent primary 
rat hepatocytes do not. Furthermore, they did not find a dose-dependent response meaning 
that after 36 h the maximal increase in proliferation (= 0.5-fold increase in thymidine 
incorporation) was reached with 8 ng/ml BMP-9. This effect started to decrease again with 10 
ng/ml and was insignificant with 80 ng/ml. Therefore, our different results might originate 
from differing cell culture conditions, species difference, and/or using different detection 
techniques. Future studies will also aim at investigating if BMP-9 might decrease the pro-
proliferative effects of known mediators like e.g. HGF. 
     
After CCl4 intoxication, we observed a transient activation of HSCs. This result fits well to 
those from Hong et al who found that after a single injection of CCl4 in rats, the α-SMA 
protein level was greatly elevated at day 3 (Shen et al., 2007). TGF-β1 has been regarded as 
the key promoter for HSC activation (Breitkopf et al., 2005) and Claus et al reported that in 
wild type mice expression of TGF-β1 peaked at day 1 after a single CCl4 treatment. The peak 
of TGF-β1 preceded that of α-SMA expression, implying that TGF-β1 is involved in HSC 
activation. But interestingly, in TGFβ1 knock-out mice which had no TGF-β1 and low TGF-
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β2 and TGF-β3, CCl4 injection still resulted in relatively small but significant expression of 
Collagen α1(I) and α-SMA, and HSC activation in vivo still occurred (Hellerbrand et al., 
1999). So TGF-β1 seems not indispensable for HSC activation even though it most likely 
enhances it leading to the maximal fibrotic effect in vivo. Other cytokines and/or pathways 
may also participate in the process of early HSC activation. In our mouse model, increased 
pSmad1 was observed as early as 3 h after CCl4 injection, but only in hepatocytes. At day 1, in 
the damaged area, few activated HSCs were detected, but at day 3, the number of α-SMA 
positive cells was significantly increased. At the same time, pSmad1 was also detected in this 
area. Our observation is consistent with the report that increase of Smad1 protein expression 
is seen at day 2 with a peak at day 3 in isolated HSCs from the acute CCl4 model (Shen et al., 
2007). This group further reported that Smad1 expression and transcriptional activity are also 
increased when HSCs activate in the acute CCl4 animal model (Shen et al., 2007). These 
observations and the facts that BMP-9 and pSmad1 expressions increased with in vitro 
activation of HSCs and that BMP-9-induced proliferation of the HSC cell line LX-2, imply 
that the Smad1 pathway participates in HSC activation in vivo. Hong et al have demonstrated 
that in rat HSCs, Smad1 expression and its phosphorylation are increased along with HSC 
activation. Adenoviruses overexpressing Smad1 or Smad1 short hairpin RNA (shRNA) 
increase or decrease α-SMA expression, respectively, in CSFC-8B, an HSC cell line (Shen et 
al., 2003). These in vitro data further support the conclusion that the Smad1 pathway plays an 
important role in activation of HSCs. Therefore, besides TGF-β induced Smad2/3 signaling 
which has been regarded as the most important pathway in HSC activation and fibrogenesis 
(Gressner and Weiskirchen, 2006), BMP/Smad1 signaling may be another critical player in 
this process. 
 
Although Smad1 signaling can be activated by both TGF-β1 and BMPs (Kretzschmar et al., 
1997b), BMPs are its dominant triggers in hepatocytes and HSCs. TGF-β1-induced Smad1 
phosphorylation is only transient, returning to basal levels within hours and at least in vitro 
this response requires higher amounts of TGF-β1 than needed for maximal activation of 
Smads 2 and 3 (data not shown). Therefore it is reasonable to hypothesize that in vivo mainly 
BMPs are the inducers of Smad1 signaling in the liver and TGF-β mainly activates the 
Smad2/3 pathway. In the bile duct ligation (BDL) model, another liver fibrosis model, 
expression of BMP-4 is markedly elevated in the fibrotic liver and presence of activated 
HSCs along with significantly increased down-stream signaling via Smad1, but also via 
ERK1/2 and p38 was described. BMP-4 directly stimulated pSmad1 and pERK1/2 expression 
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in an HSC cell line. Moreover, BMP-4 promoted transdifferentiation of HSCs, though without 
affecting their proliferation (Fan et al., 2006). Since BMP-9 is another strong inducer of 
Smad1 signaling, we investigated if BMP-9/Smad1 signal transduction played a role in early 
activation of HSCs. In vitro culture of primary mouse HSCs led to transdifferentiation, during 
which both BMP-9 and pSmad1 expression were elevated along with the increase of α-SMA 
and PCNA expression. In collaboration with P. ten Dijke’s group at the University of Leiden, 
the Netherlands, we used injection of AdALK1-Fc, an adenovirus expressing a secreted 
mutant of the BMP-9 receptor to capture BMP-9 in vivo in the chronic CCl4-induced mouse 
model of liver fibrosis. Here we found that inhibition of BMP-9 by AdALK1-Fc reduced 
collagen deposition and α-SMA expression in the liver (manuscript in preparation). Together 
with our results presented in this thesis we draw the conclusion that BMP-9 is indeed a pro-
fibrotic cytokine in vivo. Based on the fact that BMP-9, pSmad1, desmin and α-SMA 
expression were localized within the pericentral area at day 3 after CCl4 injection in vivo, it is 
speculated that the BMP-9/Smad1 pathway might play a role in the transdifferentiation of 
HSCs in vivo. It still needs to be established if overexpressed BMP-9 directly promotes liver 
fibrogenesis, but our data strongly imply that it is involved in HSC activation and TGF-β1 
mediated apoptosis of hepatocytes, both representing events that trigger fibrogenesis in vivo. 
   
Dorsomorphin, also named compound C, has been described as a potent inhibitor of AMPK 
(AMP-activated protein kinase) (Gao et al., 2008). Later, it has been discovered to also have 
high selectivity for inhibition of the BMP/Smad1 pathway (Anderson and Darshan, 2008) and 
it has been used to inhibit BMP signaling in iron homeostasis (Yu et al., 2008), osteogenesis 
(Seib et al., 2009), T cell activation and differentiation (Yoshioka et al., 2012). Interestingly, 
activation of AMPK inhibits transdifferentiation of HSCs and liver fibrosis (Adachi and 
Brenner, 2008; Lim et al., 2012). But AMPK-deficiency was not responsible for enhanced 
CCl4-induced fibrosis in vivo (da Silva Morais et al., 2010). Therefore, if inhibition of AMPK 
by Dorsomorphin happens in HSCs, it can be expected to have no influence or even act as a 
promoter on HSC activation. In our study, the presence of Dorsomorphin significantly 
inhibited HSC transdifferentiation in vitro as monitored by reduced expressions of fibrotic 
markers including α-SMA, collagen, Id-1, desmin and fibronectin. Together with the above 
discussed involvement of the BMP-9/Smad1 signaling in HSC activation, we conclude that 
the inhibitory effects of Dorsomorphin on HSC activation were dominantly related to its 
inhibitory effect on the BMPs/Smad1 pathway.  
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It has been generally accepted that liver fibrosis is a reversible dynamic process. Therefore 
anti-fibrotic treatment was often considered as tool for reducing the occurrence of liver 
cirrhosis, even liver cancer. Several candidates to be targeted in such antifibrotic therapies 
have been tested in preclinical or clinical studies and they include Interferon-γ, Angiotension 
receptor blockers, PPAR ligands, Endothelin-1 receptor antagonists and TGF-β neutralizing 
agents (Thompson and Patel, 2010). According to others’ and our study, the Smad1 pathway 
plays an important role in HSC activation and its inhibitor, Dorsomorphin can reverse this 
process. Therefore neutralization of this pathway or even of BMP-9 alone might provide 
another practical anti-fibrotic strategy in the near future which needs to be evaluated further. 
     
Besides acute and chronic liver diseases, TGF-β members have also been described to play 
important roles in various types of cancers such as gastric, liver and pancreatic cancer 
(Achyut and Yang, 2011). In premalignant cells TGF-β1 serves as a tumor suppressor, while 
in later stages of cancer, it functions as a tumor promoter. It has not been clearly clarified how 
and when TGF-β1 is converted from a tumor suppressor to a tumor promoter during 
carcinogenesis (Achyut and Yang, 2011). As for the roles of TGF-β in HCC, one explanation 
proposed by Yamazaki et al indicates that TGF-β inhibits proliferation in premalignant 
hepatocytes and early HCC cells, along with promotion of stroma formation, whereas in late 
stages of HCC, TGF-β induces cancer invasion via tumor-stromal interaction (Yamazaki et al., 
2011). During the past decades, although BMPs as well have been demonstrated to participate 
in the formation and progression of human cancer, compared to the dual roles of TGF-β1 in 
cancer development, BMPs perform quite different or may even exert completely opposite 
functions depending on the cancer cell type, the tumor microenvironment and other cell 
functions. For example, BMP-2 inhibits growth of gastric cancer cells through increasing the 
levels of p21/WAF1/CIP1, leading to cell cycle arrest in the G1-phase (Wen et al., 2004), but 
it facilitates proliferation of lung cancer cells through Smad1/5 signaling and induction of Id-1 
expression (Langenfeld et al., 2006).  
 
Nine different BMPs are up-regulated in HCC cells and their described functions in disease 
progression include cell proliferation, migration and angiogenesis (Lu et al., 2012; 
Maegdefrau and Bosserhoff, 2012; Qiu et al., 2010). BMP-4 and BMP-7 are up-regulated in 
HBx-induced HCC mouse models and in human HBV-related HCC patients and are therefore 
included to what they have defined the “most common regulators” during the transition from 
normal liver to HCC. Furthermore, their ectopic overexpression increases cell viability and 
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promotes migration in Hep3B (Lu et al., 2012). Overexpression of BMP-4 is significantly 
associated with the number of tumor nodules, TNM stage and vascular invasion, and is 
proposed as a new marker to predict the recurrence and prognosis of HCC patients (Guo et al., 
2012). Further, BMP-4 induces cell proliferation and migration in HepG2 and Hep3B (Chiu et 
al., 2012). BMP-2 induces angiogenesis in Bel7402 and SMMC7721 tumor xenografted nude 
mice, and WSS25, an antagonist of BMP-2 inhibits angiogenesis via blocking 
BMP/Smad1/Id-1 signaling in these mouse models (Qiu et al., 2010). 
 
In human cancer, variant functions for BMP-9 have been described depending on the cancer 
types. In prostate and breast cancer, BMP-9 provides tumor suppressor activity, since it 
inhibits growth, migration and invasion (Wang et al., 2011; Ye et al., 2008), whereas in 
ovarian cancer, it acts as a proliferation promoter via activation of ALK2/Smad1 signaling 
(Herrera et al., 2009). Although BMP-9 has been found to be up-regulated in HCC cell lines 
(Maegdefrau and Bosserhoff, 2012), so far, its contribution to HCC development and 
progression has not been explored.  
     
In the present study, we demonstrated that BMP-9 mRNA and protein were expressed at 
different degrees in liver tissues from HCC patients. Slightly positive (1+) staining of BMP-9 
protein was observed in 61%, and moderately to strongly positive staining (2+) in 39% of 
HCC tissue.  BMP-9 protein expression levels were higher in the cancer area than that in its 
adjacent “normal” liver tissue in 25% of the patients and were similar in both areas in 58.33% 
patients. In the remaining 16%, expression levels were even lower in the cancer area than in 
its adjacent “normal” liver tissue. Based on the finding that liver is the main organ producing 
BMP-9 (Song et al., 1995), we can expect that low levels of BMP-9 expression should always 
be detectable. Furthermore, the “normal” liver tissues investigated in the present study still 
came from HCC patients and should therefore be considered as rather damaged. Comparing 
this with our in situ hybridizations of healthy mouse livers which showed strong positivity 
only in cholangiocytes, together with the 25% of patients showing increased presence of 
BMP-9 in HCC compared to adjacent tissue, we conclude that there is a tendency of increase 
in BMP-9 in diseased liver, especially in HCC. We want to mention also that 95.12% of the 
investigated HCC patients were HBV-infected and it will be an interesting task to investigate 
in the future if HBV infection as such impacts BMP-9 expression and if there are differences 
in regard to disease etiology.  
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Expression of BMP-9 in HCC, as resolved with immunohistochemical staining, was 
significantly associated with the T stage showing stronger expression in patients with T3, 4 
than in T1, 2 patients, indicating that high levels of BMP-9 correlate with the degree of tumor 
invasion into the surrounding tissue. The Child-Pugh classification is well accepted as robust 
predictor of death in HCC (Tandon and Garcia-Tsao, 2009) and represents a measure for the 
level of liver damage: Child-Pugh B/C corresponds to reduced liver function (Mandli et al., 
2008). When comparing BMP-9 expression with the Child-Pugh class of the patients we 
found that Child-Pugh class B/C was stronger associated with the group with lower BMP-9 
levels (1+; 79%) while in patients with Child-Pugh class A the distribution was almost 50% 
(1+) and 50% (2+). This inverse correlation shows that although BMP-9 protein expression 
correlates with invasiveness of the tumor (T stage), it does not seem to increase along with 
loss of liver function as determined by Child-Pugh classification. 
     
Studying HCC cells in vitro, we found that BMP-9 promoted cell migration, a typical feature 
of mesenchymal cells. Together with the known pro-proliferative effect of BMP-9 in liver 
cells (Song et al., 1995), this observation prompted us to investigate if BMP-9 induces EMT 
in HCC cells. EMT is required for epithelial cancer cell migration and metastasis and down-
regulated epithelial (E)-cadherin and up-regulated Snail are well described features of EMT. 
E-cadherin is a Ca
2+
-dependent cell adhesion transmembrane glycoprotein, which links 
adjacent cells by homophilic interactions (Kemler, 1993), thus representing a typical marker 
for epithelial polarity. Membranous E-cadherin is down-regulated during loss of the epithelial 
phenotype and is a classical molecular hall mark of EMT. The expression of E-cadherin is 
negatively regulated by Snail at the transcriptional level. Appearance of mesenchymal 
markers like Vimentin or N-cadherin is other features typical for EMT. Indeed, besides 
promoting migration, BMP-9 down-regulated E-cadherin expression and induced Snail and 
Vimentin expression, indicating that in full contrast to its effects on primary hepatocytes, 
BMP-9 leads to EMT in HCC cells. In accordance with these in vitro findings, in HCC patient 
samples, BMP-9 expression was positively correlated with Snail expression and reversely 
correlated with E-cadherin expression, although these correlations did not reach statistical 
significance, which may be due to the relatively small number of samples. Hence, our results 
are supportive for the hypothesis that BMP-9 can promote migration and metastasis of HCC 
cells via induction of EMT.  
 
We further investigated the BMP-9 down-stream signaling pathway involved in EMT, and 
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especially in BMP-9 induced down-regulation of E-cadherin. In mesenchymal stem cells, 
BMP-9 was reported to signal via the BMP type I receptors ALK1 and ALK2 which both 
activate Smad1 signaling to mediate osteogenesis (Luo et al., 2010). We here show that  
ALK2 is expressed in both HCC cell lines tested and by using adenovirally overexpressed 
constructs, we could confirm that dominant negative or constitutive active mutants of ALKs 1 
and 2 impact E-cadherin expression levels and EMT in HLE and HepG2 cells.  
 
Downstream of ALK1/2 activation, Smad1 is activated and mediates the signal to the nucleus. 
BMP/Smad1 signaling was described to participate in different tumor types with diverse 
outcomes, either as tumor promoter or as tumor suppressor. Activation of Smad1/5 is 
correlated with TGF-β-induced growth inhibition in B-cell lymphoma (Bakkebo et al., 2010). 
In human breast cancer cells, activation of BMP-2/Smad1 signaling inhibits cancer cell 
proliferation via up-regulation of p21 (Pouliot and Labrie, 2002). In breast cancer patients and 
a corresponding xenograft mouse model, enhanced phospho-Smad1 staining was found in 
bone metastasis as compared to the primary tumor or lymph node metastases, which suggests 
that Smad1 signaling contributes to bone metastasis of breast cancer (Katsuno et al., 2008). In 
pancreatic cancer, BMP-2, 4 and 7 induce EMT and increase cancer cell invasiveness, and 
their common canonical down-stream signaling component, Smad1 is indispensable for BMP-
mediated invasiveness (Gordon et al., 2009). In line with the presence of BMP-9, Smad1 
phosphorylation was increased in HCC cells of liver samples from patients. These results 
further support the conclusion that the BMP-9/Smad1 pathway might be involved in the 
pathogenesis of HCC. However, we can at this stage not exclude that besides BMP-9, other 
members of the TGF-β superfamily (e.g. other BMPs or TGF-β itself) take part in inducing 
Smad1 phosphorylation.  
 
On the basis of the findings in HCC, it is implicated that the BMP-9/Smad1 pathway may 
function as a potential promoter in HCC via inducing EMT. Further studies with larger human 
patient sample numbers and animal models with a disturbed BMP-9 signaling pathway are 
planned to elucidate the functional implication of BMP-9 and its downstream signaling in 
liver cancer progression and to estimate its potential as new marker for HCC progression and 
prognosis as well as testing BMP-9 as novel therapeutic target to treat HCC.  
  
To discover more potential functions of BMP-9 in the liver, we performed microarray analysis 
with samples from hepatocytes treated with BMP-9 for 24 h. 32 genes were up-regulated and 
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only 4 genes were down-regulated by more than 1.4 fold. After grouping these genes, we 
found that BMP-9 might participate in detoxification, proliferation/differentiation, iron 
homeostasis, lipid transport, triglyceride metabolism and sugar metabolism. Several functions 
have been also reported by other groups. For instance, Luciana Chagas Caperuto et al reported 
that in normal rats BMP-9 may serve as HISS (hepatic insulin-sensitizing substance) to 
mediate glucose homeostasis and in the insulin-resistant rats, BMP-9 expression and 
processing is severely decreased (Caperuto et al., 2008). In line with our results, Jaroslav 
Truksa et al demonstrated that BMP-9 is the most potent inducer of murine hepcidin 
expression, which is a peptide playing key role in iron homeostasis (Truksa et al., 2006). 
Therefore, besides liver regeneration and HCC, BMP-9 might additionally function in liver 
diseases related to metabolism like NASH (non-alcoholic steatohepatitis) and 
haemochromatosis.  
      
In summary, our data indicate that BMP-9 may directly or indirectly play a role in hepatocyte 
apoptosis, HSC transdifferentioation and HCC progression. Therefore, our data may lead to 
novel therapeutic options based on interference with the BMP-9/Smad1 pathway in various 
liver diseases.  
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6. Abbreviations 
 
ALT, Alanine aminotransferase 
AST, Aspartate aminotransferase 
APAF1, Apoptotic protease-activator factor-1 
AIF, Apoptosis-inducing factor 
aHSC, Activated HSCs 
ACVR2A, Activin receptor Type 2 
ActRIIA, Activin A receptor type IIA 
ActRIIB, Activin A receptor type IIB 
ALK-1, Activin receptor-like kinase-1 
AMH, Anti-Mülerian hormone   
Ad, Adenovirus 
AMPK, AMP-activated protein kinase 
BMP-9, Bone morphogenetic protein-9 
BMPRII, BMP receptor type II 
BMPR-IA, BMP receptor type IA 
BDL, Bile duct ligation 
cDNA, Complementary DNA 
cRNA, Copy RNA 
caALK1, Constitutive active ALK1 
caALK2, Constitutive active ALK2 
COX-2, Cyclooxygenase-2 
CCl4, Carbon tetrachloride 
Cyp2E1, Cytochrome P-450 IIE1 
dnALK1/2, Dominant negative ALK1/2 
DMSO, Dimethylsulfoxide 
DM, Dorsomorphin 
DEPC, Diethylpyrocarbonate 
DIG, Digoxigenin 
DAB, 3,3'-diaminobenzidine tetrahydrochloride                                                                       
ERK, Extracellular signal-regulated kinase     
ECM, Extracellular matrix 
EMT, Epithelial-mesenchymal transition 
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FOXO3A, O forkhead box transcription factor-3A 
GSK3β, Glycogen synthase kinase3β 
GDF, Growth and differentiation factor 
GAPDH, Glyceraldehyde-3-phosphate dehydrogenase 
HNF-4, Hepatocyte nuclear factore-4  
HISS, Hepatic insulin-sensitizing substance 
HHT, Hereditary hemorrhagic telangiectasia 
HGF, Hepatocyte growth factor 
HCC, Hepatocellular carcinoma 
HE, Hematoxylin and eosin 
HBV, Hepatitis B virus 
HCV, Hepatitis C virus 
HSC, Hepatic stellate cell 
Id, Inhibitor of differentiation  
IHC, Immunohistochemistry 
IF, Immunofluorescence 
ISH, In situ hybridization 
I-Smads, Inhibitory-Smads 
JNK, C-Jun N-terminal kinases 
LacZ, β-galactosidase 
LDH, Lactate dehydrogenase 
MIS, Mülerian inhibiting substance 
MH1, N-terminal Mad Homology 1 
MEK, Mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 
mHC, Mouse hepatocyte 
MAPK, Mitogen activated protein kinase 
NBT/BCIP, Nitro blue tetrazolium chloride/5-Bromo-4-chloro-3-indolyl phosphate 
NOX4, NADPH oxidase-4 
NASH, Non-alcoholic steatohepatitis 
NKT, Natural killer T cells 
PCNA, Proliferating Cell Nuclear Antigen 
PFA, Paraformaldehyde 
PDGF, Platelet derived growth factor 
PPIA, Peptidylprolyl isomerase A 
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R-Smads, Receptor-Smads 
RT-PCR, Reverse transcription-polymerase chain reaction 
ROS, Reactive oxygen species 
SSC, Saline-sodium citrate 
SSXS C-terminal, Phosphorylation site of R-Smads 
shRNA, Short hairpin RNA 
α-SMA, α-smooth muscle actin 
TGF-β, Transforming growth factor-β  
TNFR, Tumor necrosis factor receptor 
TIMP-1, Tissue inhibitor of metalloproteinase-1 
TNF-α, Tumor necrosis factor-α 
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